CRITERIA FOR EVALUATING DISEASE RESPONSE AND
MYELOMA TREATED BY HIGH-DOSE THERAPY AND H

British Journal of Haematology

102, 1115-1123

DOI: 10.1046/j.1365-2141.1998.00930.x

Citation Report

#	Article	IF	Citations
1	CD34+ -selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. British Journal of Haematology, 1999, 104, 166-177.	1.2	37
2	The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. British Journal of Haematology, 1999, 106, 737-743.	1.2	26
3	USE OF QUANTITATIVE ASO-PCR TO PREDICT RELAPSE IN MULTIPLE MYELOMA. British Journal of Haematology, 1999, 105, 317-319.	1.2	8
4	Detection of Bence-Jones protein in practice. Annals of Clinical Biochemistry, 2000, 37, 563-570.	0.8	30
5	Myelomaâ€"the Elusive Cure. Hematology, 2000, 5, 27-39.	0.7	0
6	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. British Journal of Haematology, 2000, 109, 138-147.	1.2	69
7	Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. British Journal of Haematology, 2000, 109, 89-96.	1.2	210
8	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 2000, 109, 438-446.	1.2	100
9	CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. British Journal of Haematology, 2000, 109, 571-575.	1.2	14
10	Progress in haematopoietic stem cell transplantation for multiple myeloma. Journal of Internal Medicine, 2000, 248, 185-201.	2.7	35
11	Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Bone Marrow Transplantation, 2000, 26, 621-626.	1.3	6
12	High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplantation, 2000, 26, 845-849.	1.3	46
13	Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplantation, 2000, 26, 851-858.	1.3	20
14	Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 2000, 26, 963-969.	1.3	88
15	Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia, 2000, 14, 1310-1313.	3.3	70
16	The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia, 2000, 14, 1493-1499.	3.3	18
17	Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplantation, 2000, 26, 45-50.	1.3	33
18	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood, 2000, 96, 355-357.	0.6	91

#	Article	IF	Citations
19	Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood, 2000, 96, 2697-2702.	0.6	40
20	High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment. Journal of Clinical Oncology, 2000, 18, 2843-2851.	0.8	91
21	Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma. Journal of Clinical Oncology, 2000, 18, 804-804.	0.8	161
22	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. Journal of Clinical Oncology, 2000, 18, 2273-2281.	0.8	153
23	Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning. Acta OncolÃ³gica, 2000, 39, 837-841.	0.8	21
24	European Group for Blood and Marrow Transplantation Registry studies in multiple Myeloma. Seminars in Hematology, 2001, 38, 219-225.	1.8	60
25	Tumour Kinetics in Multiple Myeloma Before, During, and After Treatment. Leukemia and Lymphoma, 2001, 40, 373-384.	0.6	5
26	Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Annals of Oncology, 2001, 12, 105-108.	0.6	5
27	Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 2001, 98, 3846-3848.	0.6	114
28	Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 2001, 98, 2229-2238.	0.6	350
29	Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Annals of Hematology, 2001, 80, 345-348.	0.8	24
30	Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Annals of Hematology, 2001, 80, 393-397.	0.8	25
31	The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 2001, 112, 814-819.	1.2	103
32	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	1.2	73
33	Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2001, 27, 21-25.	1.3	23
34	Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bone Marrow Transplantation, 2001, 28, 137-143.	1.3	10
35	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 665-672.	1.3	14
36	Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 957-962.	1.3	17

#	Article	IF	Citations
37	Thalidomide in refractory and relapsing multiple myeloma. Seminars in Oncology, 2001, 28, 588-592.	0.8	29
38	Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. European Journal of Haematology, 2001, 66, 238-244.	1.1	38
39	Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplantation, 2001, 27, 821-828.	1.3	34
40	High-dose therapy in multiple myeloma. Annals of Oncology, 2002, 13, 49-54.	0.6	8
41	Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies. Journal of Clinical Oncology, 2002, 20, 4022-4031.	0.8	119
42	153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nuclear Medicine Communications, 2002, 23, 1099-1106.	0.5	20
43	Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood, 2002, 100, 3095-3100.	0.6	194
44	Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood, 2002, 100, 755-760.	0.6	245
45	Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood, 2002, 100, 3919-3924.	0.6	178
46	Stem cell transplantation for the management of primary systemic amyloidosis. American Journal of Medicine, 2002, 113, 549-555.	0.6	157
47	Minimal residual disease monitoring in multiple myeloma. Best Practice and Research in Clinical Haematology, 2002, 15, 197-222.	0.7	44
48	Molecular Methods for Detection and Quantification of Myeloma Cells after Bone Marrow Transplantation: Comparison between Real-Time Quantitative and Nested PCR. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 971-976.	1.8	9
49	Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomedicine and Pharmacotherapy, 2002, 56, 133-138.	2.5	16
50	Current treatment strategies for multiple myeloma. European Journal of Internal Medicine, 2002, 13, 85-95.	1.0	7
51	Simple Method for Quantification of Bence Jones Proteins. Clinical Chemistry, 2002, 48, 2202-2207.	1.5	10
52	MANAGEMENT OF MULTIPLE MYELOMA. Reviews in Clinical and Experimental Hematology, 2002, 6, 253-275.	0.1	13
53	Real-time polymerase chain reaction in multiple myeloma. Experimental Hematology, 2002, 30, 529-536.	0.2	24
54	Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Annals of Hematology, 2002, 81, 119-123.	0.8	29

#	Article	IF	Citations
55	Negative selection of peripheral blood stem cells â€˜to support a tandem autologous transplantation â€˜programme in multiple myeloma. British Journal of Haematology, 2002, 116, 202-210.	1.2	40
56	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. British Journal of Haematology, 2002, 117, 890-892.	1.2	24
57	Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. British Journal of Haematology, 2002, 117, 605-612.	1.2	8
58	Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplantation, 2002, 30, 367-373.	1.3	130
59	Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an â€˜operational cureâ€™?. Bone Marrow Transplantation, 2002, 30, 479-484.	1.3	13
60	Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1470-1477.	3.3	36
61	Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma. International Journal of Hematology, 2003, 77, 232-238.	0.7	5
62	Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Annals of Hematology, 2003, 82, 558-564.	0.8	15
63	Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and Î²2 -microglobulin in multiple myeloma. European Journal of Haematology, 2003, 70, 34-42.	1.1	44
64	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 127-131.	0.8	86
65	Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?. Seminars in Oncology, 2003, 30, 329-331.	0.8	0
66	Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. International Journal of Cancer, 2003, 106, 455-457.	2.3	84
67	Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology, 2003, 73, 169-175.	2.0	24
68	Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution. American Journal of Hematology, 2003, 73, 267-272.	2.0	17
69	Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. Journal of Thrombosis and Haemostasis, 2003, 1, 445-449.	1.9	102
70	Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo EspaÃ±ol de SÃndromes Linfoproliferativos/Trasplante AutÃ³logo de MÃ©dula Ã“sea phase II trial. British Journal of Haematology, 2003, 120, 296-303.	1.2	31
71	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. British Journal of Haematology, 2003, 121, 104-108.	1.2	90
72	Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. British Journal of Haematology, 2003, 121, 411-418.	1.2	100

#	Article	IF	Citations
73	Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 2003, 121, 749-757.	1.2	1,887
74	Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology, 2003, 122, 607-616.	1.2	117
75	T-cell receptor excision circles: a novel prognostic parameter for the outcome of transplantation in multiple myeloma patients. British Journal of Haematology, 2003, 122, 795-801.	1.2	26
76	T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly. British Journal of Haematology, 2003, 123, 309-322.	1.2	44
77	Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology, 2003, 123, 631-636.	1.2	119
78	Dissociation of putative graft-versus -haematopoiesis and graft-versus -myeloma effects in patients with rapidly progressive multiple myeloma*. British Journal of Haematology, 2003, 123, 646-653.	1.2	16
79	The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British Journal of Haematology, 2003, 123, 886-895.	1.2	21
80	Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplantation, 2003, 31, 157-161.	1.3	18
81	Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplantation, 2003, 31, 163-170.	1.3	62
82	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplantation, 2003, 31, 767-773.	1.3	15
83	Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplantation, 2003, 31, 973-979.	1.3	38
84	Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplantation, 2003, 32, 629-631.	1.3	24
85	A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplantation, 2003, 32, 593-599.	1.3	42
86	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2003, 32, 791-793.	1.3	10
87	Autologous stem cell transplantation in multiple myeloma patients <60 vs â©¾60 years of age. Bone Marrow Transplantation, 2003, 32, 1135-1143.	1.3	70
88	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2003, 349, 2495-2502.	13.9	938
91	Velcade Â® : U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist, 2003, 8, 508-513.	1.9	562
92	Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treatment Reviews, 2003, 29, 33-39.	3.4	79

#	Article	IF	Citations
93	Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biology of Blood and Marrow Transplantation, 2003, 9, 257-265.	2.0	89
94	Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment. European Journal of Cancer, 2003, 39, 9-18.	1.3	14
95	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biology of Blood and Marrow Transplantation, 2003, 9, 312-319.	2.0	31
96	Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biology of Blood and Marrow Transplantation, 2003, 9, 397-404.	2.0	18
97	High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma. New England Journal of Medicine, 2003, 348, 1875-1883.	13.9	1,648
98	Autologous Blood Cell Transplantation in Multiple Myeloma: Impact of CD34+Cell Selection with Long Follow-Up. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 63-70.	1.8	3
99	Bortezomib Treatment for Multiple Myeloma. Annals of Pharmacotherapy, 2003, 37, 1825-1830.	0.9	18
100	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 2003, 348, 2609-2617.	13.9	2,460
101	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398.	2.0	374
102	Bortezomib in Multiple Myeloma. New England Journal of Medicine, 2003, 349, 1287-1288.	13.9	3
103	Bone marrow immunohistology of plasma cell neoplasms. Journal of Clinical Pathology, 2003, 56, 406-411.	1.0	38
104	Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood, 2003, 102, 69-77.	0.6	129
105	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	0.6	382
106	166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood, 2003, 102, 2684-2691.	0.6	109
107	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood, 2003, 102, 1588-1594.	0.6	113
108	Transplantation for multiple myeloma: who, when, how often?. Blood, 2003, 102, 3469-3477.	0.6	76
109	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood, 2003, 102, 1927-1929.	0.6	176
110	Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood, 2003, 102, 2345-2350.	0.6	90

#	Article	IF	Citations
111	Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. Cancer Control, 2003, 10, 361-369.	0.7	269
112	High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study. Journal of Korean Medical Science, 2003, 18, 673.	1.1	8
113	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. Leukemia and Lymphoma, 2004, 45, 2275-2279.	0.6	14
114	Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients. Clinical Cancer Research, 2004, 10, 8301-8308.	3.2	40
115	Bortezomib as a Potential Treatment for Prostate Cancer. Cancer Research, 2004, 64, 5036-5043.	0.4	120
116	Second Autologous Transplantation for Multiple Myeloma Patients Relapsing after the First Autograft â€“ a Pilot Study for the Evaluation of Experimental Maintenance Therapies. Report of the Prospective Non-Randomized Pilot Study of the Czech Myeloma Group. Oncology Research and Treatment, 2004, 27, 275-279.	0.8	14
117	Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. Clinical Cancer Research, 2004, 10, 8170-8176.	3.2	63
118	Accelerated Approval of Oncology Products: A Decade of Experience. Journal of the National Cancer Institute, 2004, 96, 1500-1509.	3.0	83
119	Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clinical Cancer Research, 2004, 10, 3954-3964.	3.2	316
120	Bortezomib, a Newly Approved Proteasome Inhibitor for the Treatment of Multiple Myeloma: Nursing Implications. Clinical Journal of Oncology Nursing, 2004, 8, 473-480.	0.3	35
121	Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone â€“ a case report. The Hematology Journal, 2004, 5, 361-363.	2.0	16
122	Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. The Hematology Journal, 2004, 5, 312-317.	2.0	30
123	Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Internal Medicine Journal, 2004, 34, 576-578.	0.5	12
124	Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2004, 125, 470-476.	1.2	104
125	Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. British Journal of Haematology, 2004, 125, 756-765.	1.2	14
126	Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. British Journal of Haematology, 2004, 126, 665-674.	1.2	69
127	A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 2004, 126, 792-798.	1.2	18
128	A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 2004, 127, 165-172.	1.2	632

#	Article	IF	Citations
129	A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British Journal of Haematology, 2004, 127, 299-304.	1.2	117
130	High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. British Journal of Haematology, 2004, 127, 543-551.	1.2	62
131	The proteasome: a suitable antineoplastic target. Nature Reviews Cancer, 2004, 4, 349-360.	12.8	1,130
132	High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplantation, 2004, 33, 61-64.	1.3	50
133	Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplantation, 2004, 33, 623-628.	1.3	17
134	High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplantation, 2004, 34, 69-76.	1.3	25
135	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 77-84.	1.3	66
136	A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplantation, 2004, 34, 149-154.	1.3	40
137	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	1.3	82
138	Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 419-423.	1.3	8
139	Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 2004, 34, 1025-1031.	1.3	102
140	Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplantation, 2004, 34, 1057-1065.	1.3	69
141	The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia, 2004, 18, 856-863.	3.3	157
142	G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia, 2004, 18, 1078-1084.	3.3	45
143	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia, 2004, 18, 1420-1426.	3.3	61
144	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European Journal of Haematology, 2004, 72, 403-409.	1.1	43
145	Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. European Journal of Haematology, 2004, 73, 402-406.	1.1	114
146	The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5, 417-421.	7.7	723

#	Article	IF	Citations
147	Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation. European Journal of Haematology, 2004, 72, 26-31.	1.1	8
148	Clinical update: Novel targets in multiple myeloma. Seminars in Oncology, 2004, 31, 27-32.	0.8	16
149	Use of Proteasome Inhibition in the Treatment of Lung Cancer. Clinical Lung Cancer, 2004, 6, S89-S96.	1.1	20
150	Unrelated Cord Blood Transplantation with a Reduced-Intensity Conditioning Regimen following Autologous Transplantation for Multiple Myeloma. International Journal of Hematology, 2004, 80, 377-380.	0.7	8
151	Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Reviews, 2004, 18, 17-37.	2.8	59
152	Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer, 2004, 100, 2607-2612.	2.0	64
153	The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematological Oncology, 2004, 22, 159-168.	0.8	27
154	Methylation profiling in multiple myeloma. Leukemia Research, 2004, 28, 379-385.	0.4	43
155	Proteasome inhibition in hematologic malignancies. Annals of Medicine, 2004, 36, 304-314.	1.5	59
156	Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood, 2004, 104, 3400-3407.	0.6	204
157	The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood, 2004, 103, 4362-4364.	0.6	171
158	Bortezomib in multiple myeloma: treatment approach and outcomes. European Journal of Cancer, Supplement, 2004, 2, 12-17.	2.2	3
159	Multiple Myeloma. New England Journal of Medicine, 2004, 351, 1860-1873.	13.9	1,291
160	Update on the Proteasome Inhibitor Bortezomibin Hematologic Malignancies. Clinical Lymphoma and Myeloma, 2004, 4, 230-237.	2.1	32
161	Proteasome Inhibition. American Journal of Cancer, 2004, 3, 271-279.	0.4	0
162	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	1.4	34
163	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 2004, 10, 698-708.	2.0	103
164	Free Lightâ€Chain Proteinuria and Normal Renal Histopathology and Function in 11 Dogs Exposed to Leishmania infantum, Ehrlichia canis, and Babesia canis. Journal of Veterinary Internal Medicine, 2004, 18, 618-624.	0.6	21

#	Article	IF	Citations
165	Recent advances in the management of multiple myeloma. Seminars in Hematology, 2004, 41, 21-26.	1.8	9
166	Multiple myeloma. Lancet, The, 2004, 363, 875-887.	6.3	209
167	The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 371-378.	2.3	6
168	Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma. Hematology, 2004, 9, 17-33.	0.7	13
169	Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood, 2004, 103, 4056-4061.	0.6	93
170	Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood, 2004, 104, 3361-3363.	0.6	106
171	Targeting the Proteasome in Cancer Therapy. , 2005, , 243-274.		1
172	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 2005, 105, 4532-4539.	0.6	228
173	Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 2005, 105, 3058-3065.	0.6	296
174	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood, 2005, 105, 4784-4791.	0.6	80
175	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 2005, 106, 35-39.	0.6	333
176	Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 2005, 106, 2977-2981.	0.6	102
177	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, 4050-4053.	0.6	604
178	Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leukemia Research, 2005, 29, 587-590.	0.4	59
179	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leukemia Research, 2005, 29, 961-966.	0.4	56
180	Bcl-xl Expression in Multiple Myeloma. Medical Oncology, 2005, 22, 183-190.	1.2	10
181	Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group. International Journal of Hematology, 2005, 81, 342-348.	0.7	14
182	Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. International Journal of Hematology, 2005, 82, 243-247.	0.7	13

#	Article	IF	Citations
183	Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. British Journal of Haematology, 2005, 128, 496-502.	1.2	40
184	Serum free light chains for monitoring multiple myeloma. British Journal of Haematology, 2005, 128, 405-406.	1.2	14
185	PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 2005, 129, 755-762.	1.2	313
186	Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology, 2005, 129, 763-770.	1.2	112
187	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 2005, 129, 776-783.	1.2	378
188	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 2005, 131, 71-73.	1.2	180
189	Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. British Journal of Haematology, 2005, 131, 329-337.	1.2	7
190	Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine, 2005, 11, 1230-1237.	15.2	282
191	Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplantation, 2005, 35, 159-164.	1.3	41
192	Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplantation, 2005, 35, 675-681.	1.3	26
193	Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma. Bone Marrow Transplantation, 2005, 35, 979-984.	1.3	4
194	Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation, 2005, 35, 971-977.	1.3	64
195	An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplantation, 2005, 36, 19-24.	1.3	22
196	First-line thalidomideâ€“dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplantation, 2005, 36, 193-198.	1.3	33
197	Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 2005, 36, 597-600.	1.3	92
198	Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140â€‰mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation, 2005, 36, 771-779.	1.3	57
199	Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplantation, 2005, 36, 963-969.	1.3	53
200	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia, 2005, 19, 118-125.	3.3	46

#	Article	IF	Citations
201	The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 2005, 19, 1969-1976.	3.3	99
202	High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genetics and Cytogenetics, 2005, 161, 116-124.	1.0	23
203	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Experimental Hematology, 2005, 33, 920-927.	0.2	40
204	Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. European Journal of Haematology, 2005, 74, 40-46.	1.1	47
205	Autologous stem cell transplantation in patients with high-risk plasmacytoma. European Journal of Haematology, 2005, 74, 402-406.	1.1	15
206	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology, 2005, 75, 376-383.	1.1	61
207	Multiple myeloma in elderly patients: prognostic factors and outcome. European Journal of Haematology, 2005, 75, 370-375.	1.1	48
208	Bortezomib in recurrent and/or refractory multiple myeloma. Cancer, 2005, 103, 1195-1200.	2.0	218
209	Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer, 2005, 104, 1428-1433.	2.0	77
210	Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer, 2005, 104, 1794-1807.	2.0	159
211	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer, 2005, 104, 2141-2148.	2.0	99
212	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	2.0	1,179
213	IgD multiple myeloma?a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Annals of Hematology, 2005, 84, 115-117.	0.8	30
214	Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Annals of Hematology, 2005, 84, 311-316.	0.8	29
215	Autologous stem cell transplantation in myeloma: the St Jamesâ€™s Hospital experience, 1997â€“2003. Irish Journal of Medical Science, 2005, 174, 26-32.	0.8	2
216	Treatment of myeloma in patients not eligible for transplantation. Current Treatment Options in Oncology, 2005, 6, 241-253.	1.3	9
217	Novel therapy in multiple myeloma. Investigational New Drugs, 2005, 23, 411-415.	1.2	7
218	A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma. Journal of Korean Medical Science, 2005, 20, 598.	1.1	6

#	Article	IF	Citations
219	Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol. Sao Paulo Medical Journal, 2005, 123, 266-270.	0.4	1
220	Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patientswith multiple myeloma. Annals of Oncology, 2005, 16, 219-221.	0.6	7
221	Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Annals of Oncology, 2005, 16, 1530-1538.	0.6	30
222	Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. The Hematology Journal, 2005, 5, 559-564.	2.0	10
223	Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncology, 2005, 1, 161-167.	1.1	33
224	Development of Effective New Treatments for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 7207-7211.	0.8	19
225	Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Annals of Oncology, 2005, 16, 611-617.	0.6	13
226	Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Annals of Oncology, 2005, 16, 1824-1828.	0.6	100
227	Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 4381-4389.	0.8	23
228	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 2005, 106, 3777-3784.	0.6	306
229	Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance. Journal of Clinical Oncology, 2005, 23, 7069-7073.	0.8	91
230	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticancer Therapy, 2005, 5, 465-476.	1.1	14
231	The Changing Treatment Paradigm in Patients With Newly Diagnosed Multiple Myeloma: Implications for Nursing. Oncology Nursing Forum, 2005, 32, E127-E138.	0.5	12
232	The predictive power of serum Î²/Î» ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Clinical Chemistry and Laboratory Medicine, 2005, 43, 32-7.	1.4	3
233	Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma. Acta Haematologica, 2005, 114, 170-173.	0.7	28
234	Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients. Journal of Clinical Oncology, 2005, 23, 4089-4099.	0.8	96
235	Comparison of Ancillary Studies in the Detection of Residual Disease in Plasma Cell Myeloma in Bone Marrow. American Journal of Clinical Pathology, 2005, 125, 895-904.	0.4	5
236	Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide. Seminars in Hematology, 2005, 42, S9-S15.	1.8	62

#	Article	IF	Citations
237	Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic Proceedings, 2005, 80, 1578-1582.	1.4	31
238	Overview of drug therapy for multiple myeloma. Journal of Oncology Pharmacy Practice, 2005, 11, 83-100.	0.5	14
239	Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treatment Reviews, 2005, 31, 591-602.	3.4	69
240	Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Transplant Immunology, 2005, 15, 173-177.	0.6	7
241	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
242	Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2005, 6, 84-88.	1.4	7
243	Induction Therapy Before Transplantation in Multiple Myeloma: New Strategies to Achieve Complete Response. Clinical Lymphoma and Myeloma, 2005, 6, 96-101.	1.4	1
244	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. Journal of Clinical Oncology, 2005, 23, 630-639.	0.8	526
245	Novel biological therapies for the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 619-634.	0.7	46
246	Bortezomib: A valuable new antineoplastic strategy in multiple myeloma. Acta OncolÃ³gica, 2005, 44, 440-448.	0.8	35
247	The Proteasome as a Target for Cancer Treatment. American Journal of Cancer, 2005, 4, 359-372.	0.4	5
248	Management Strategies for Relapsed Multiple Myeloma. American Journal of Cancer, 2006, 5, 393-409.	0.4	2
249	The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide â€“ vincristine â€“ doxorubicin â€“ methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia and Lymphoma, 2006, 47, 2335-2338.	0.6	43
250	Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leukemia and Lymphoma, 2006, 47, 1553-1556.	0.6	30
251	New horizons in multiple myeloma therapy. Expert Review of Anticancer Therapy, 2006, 6, 1483-1501.	1.1	1
252	A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasoneâ€"Reversible posterior lobe leukoencephalopathy. Leukemia and Lymphoma, 2006, 47, 1431-1434.	0.6	14
253	Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1360-1364.	0.6	7
254	Bortezomib is effective in primary plasma cell leukemia. Leukemia and Lymphoma, 2006, 47, 1670-1673.	0.6	33

#	Article	IF	Citations
255	Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: A clinical study of 110 patients in China. Leukemia and Lymphoma, 2006, 47, 2593-2600.	0.6	4
256	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, The, 2006, 367, 825-831.	6.3	775
257	Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 889-895.	1.4	100
258	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
259	Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 469-474.	1.4	16
260	Intermediate-Dose Melphalan (100 mg/m2)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 475-477.	1.4	22
261	Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 210-216.	1.4	42
262	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine, 2006, 57, 33-47.	5.0	317
263	Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2006, 24, 937-944.	0.8	205
264	Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clinical Therapeutics, 2006, 28, 953-959.	1.1	18
265	New Staging Systems Can Predict Prognosis of Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation as First-Line Therapy. Biology of Blood and Marrow Transplantation, 2006, 12, 837-844.	2.0	20
266	Clinical Efficacy of Thalidomide Containing Regimens as a Primary Therapy in Patients with Multiple Myeloma. The Korean Journal of Hematology, 2006, 41, 83.	0.7	1
267	Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. Hematology American Society of Hematology Education Program, 2006, 2006, 338-347.	0.9	15
269	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, Volume 1-Issues 3 & 4, 0-0.	4.7	1
270	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 2006, 108, 2165-2172.	0.6	373
271	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 2006, 108, 3289-3294.	0.6	639
272	Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood, 2006, 107, 2578-2584.	0.6	62
273	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107, 3378-3383.	0.6	230

#	Article	IF	Citations
274	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 2006, 107, 3384-3388.	0.6	64
275	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood, 2006, 107, 3415-3416.	0.6	75
276	Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood, 2006, 108, 2159-2164.	0.6	101
278	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Current Opinion in Oncology, 2006, 18, 598-608.	1.1	32
279	Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thrombosis Journal, 2006, 4, 11.	0.9	32
280	Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British Journal of Haematology, 2006, 132, 155-161.	1.2	39
281	Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology, 2006, 132, 410-451.	1.2	234
282	A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2006, 132, 584-593.	1.2	218
283	Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. British Journal of Haematology, 2006, 133, 526-529.	1.2	18
284	sVE-cadherin and sCD146 serum levels in patients with multiple myeloma. International Journal of Laboratory Hematology, 2006, 28, 36-39.	0.2	11
285	Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplantation, 2006, 37, 65-72.	1.3	11
286	Cure of multiple myeloma â€“ more hype, less reality. Bone Marrow Transplantation, 2006, 37, 1-18.	1.3	26
287	Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplantation, 2006, 37, 731-737.	1.3	100
288	Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2006, 37, 825-829.	1.3	32
289	Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2006, 37, 937-943.	1.3	6
290	High-dose melphalan (200â€‰mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (â©¾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplantation, 2006, 37, 917-922.	1.3	96
291	Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplantation, 2006, 37, 1099-1102.	1.3	23
292	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2006, 37, 1135-1141.	1.3	98

#	Article	IF	Citations
293	Results of a phase I/II trial adding carmustine (300â€‰mg/m2) to melphalan (200â€‰mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia, 2006, 20, 345-349.	3.3	13
294	Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia, 2006, 20, 1341-1352.	3.3	115
295	International uniform response criteria for multiple myeloma. Leukemia, 2006, 20, 1467-1473.	3.3	2,332
296	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leukemia Research, 2006, 30, 283-285.	0.4	17
297	Different Î³/Î´ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leukemia Research, 2006, 30, 529-535.	0.4	14
298	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. International Journal of Hematology, 2006, 83, 309-313.	0.7	32
299	Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisoneâ€”a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 2006, 132, 205-212.	1.2	175
300	Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Annals of Hematology, 2006, 85, 132-133.	0.8	18
301	Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. Annals of Hematology, 2006, 85, 394-399.	0.8	10
302	Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma. Annals of Hematology, 2006, 85, 627-628.	0.8	7
303	An unusual case of pulmonary hypertension in a young male. Internal and Emergency Medicine, 2006, 1, 127-132.	1.0	1
304	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. European Journal of Haematology, 2006, 76, 273-277.	1.1	51
305	Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology, 2006, 77, 233-238.	1.1	146
306	Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?. European Journal of Haematology, 2006, 77, 239-244.	1.1	17
307	Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Experimental Hematology, 2006, 34, 770-775.	0.2	66
308	Bortezomib: an effective agent in extramedullary disease in multiple myeloma. European Journal of Haematology, 2006, 76, 405-408.	1.1	129
309	First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. European Journal of Haematology, 2006, 76, 399-404.	1.1	51
310	Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. European Journal of Haematology, 2006, 77, 1-6.	1.1	16

#	Article	IF	Citations
311	Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. European Journal of Haematology, 2006, 77, 486-492.	1.1	30
312	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 2006, 106, 1084-1089.	2.0	69
313	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:. Cancer, 2006, 106, 1316-1319.	2.0	133
314	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, 2006, 106, 2171-2180.	2.0	45
315	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematological Oncology, 2006, 24, 205-211.	0.8	10
316	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer, 2006, 119, 1728-1731.	2.3	153
317	High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. American Journal of Hematology, 2006, 81, 973-978.	2.0	7
318	Bortezomib for multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 1337-1346.	0.9	12
319	Pharmacotherapy of multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 767-781.	0.9	4
320	Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 29-37.	0.6	60
321	A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leukemia and Lymphoma, 2006, 47, 39-42.	0.6	43
322	Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. Leukemia and Lymphoma, 2006, 47, 171-173.	0.6	38
324	Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. Journal of Clinical Oncology, 2006, 24, 929-936.	0.8	464
325	New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. Current Pharmaceutical Design, 2006, 12, 327-340.	0.9	31
326	United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy. Clinical Cancer Research, 2006, 12, 2955-2960.	3.2	326
327	Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2006, 24, 976-982.	0.8	88
328	Four-Color Flow Cytometric Analysis of Myeloma Plasma Cells. American Journal of Clinical Pathology, 2006, 126, 908-915.	0.4	17
329	Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma. Acta Haematologica, 2006, 116, 203-206.	0.7	12

#	Article	IF	Citations
330	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. Oncologist, 2006, 11, 51-61.	1.9	102
331	The efficacy of low dose thalidomide in refractory/relapsed myelomaâ€"a retrospective audit. Leukemia and Lymphoma, 2006, 47, 2409-2411.	0.6	5
332	Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opinion on Investigational Drugs, 2006, 15, 117-130.	1.9	21
333	Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1103-1109.	0.6	49
334	Comparison of Ancillary Studies in the Detection of Residual Disease in Plasma Cell Myeloma in Bone Marrow. American Journal of Clinical Pathology, 2006, 125, 895-904.	0.4	16
335	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	0.8	301
336	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 2007, 92, 50-55.	1.7	318
337	Multiple Myeloma: Molecular Imaging with C-Methionine PET/CTâ€"Initial Experience. Radiology, 2007, 242, 498-508.	3.6	105
338	A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 2007, 13, 1762-1768.	3.2	115
339	Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01â€21. Oncologist, 2007, 12, 99-106.	1.9	52
340	The Role of High-Dose Chemotherapy Supported by Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma: Implications for Nursing. Clinical Journal of Oncology Nursing, 2007, 11, 569-589.	0.3	6
341	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research, 2007, 67, 2982-2989.	0.4	236
342	Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement. Acta OncolÃ³gica, 2007, 46, 262-264.	0.8	9
343	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 2007, 92, 546-549.	1.7	160
344	Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leukemia and Lymphoma, 2007, 48, 759-766.	0.6	27
345	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. Leukemia and Lymphoma, 2007, 48, 754-758.	0.6	16
346	Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. Journal of Clinical Pathology, 2007, 61, 213-216.	1.0	37
347	Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. Journal of Clinical Oncology, 2007, 25, 1121-1128.	0.8	369

#	Article	IF	Citations
348	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. Journal of Clinical Oncology, 2007, 25, 3892-3901.	0.8	607
349	Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2007, 357, 2123-2132.	13.9	1,365
350	Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients. Clinical Cancer Research, 2007, 13, 1503-1510.	3.2	69
351	VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Annals of Oncology, 2007, 18, 1369-1375.	0.6	59
352	An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-Î±2b in patients with multiple myeloma maintained on a steady dose of interferon-Î±2b. Annals of Oncology, 2007, 18, 1388-1394.	0.6	22
353	New Drugs for Myeloma. Oncologist, 2007, 12, 664-689.	1.9	145
354	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research, 2007, 13, 7073-7079.	3.2	99
355	Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica, 2007, 92, 1411-1414.	1.7	124
356	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. Journal of Clinical Oncology, 2007, 25, 4452-4458.	0.8	106
357	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. Journal of Clinical Oncology, 2007, 25, 2434-2441.	0.8	329
358	Relationship Between Depth of Response and Outcome in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 4933-4937.	0.8	40
359	The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica, 2007, 92, 1149-1150.	1.7	71
360	Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma. Haematologica, 2007, 92, 1246-1249.	1.7	27
361	Neuropathy in multiple myeloma treated with thalidomide. Neurology, 2007, 69, 573-581.	1.5	121
362	Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica, 2007, 92, 1083-1090.	1.7	52
363	Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 2007, 109, 457-464.	0.6	212
364	Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood, 2007, 109, 3588-3594.	0.6	167
365	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 2007, 109, 465-470.	0.6	259

#	Article	IF	Citations
366	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 2007, 110, 3557-3560.	0.6	485
367	Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood, 2007, 110, 287-295.	0.6	26
368	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 2007, 109, 3177-3188.	0.6	379
369	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood, 2007, 109, 2604-2606.	0.6	242
370	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood, 2007, 110, 827-832.	0.6	167
371	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 149-162.	2.3	59
372	Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica, 2007, 92, 1505-1512.	1.7	33
373	Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 2007, 12, 235-239.	0.7	101
374	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 423-432.	2.0	40
375	Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2007, 13, 543-549.	2.0	29
376	Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 925-931.	2.0	44
377	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biology of Blood and Marrow Transplantation, 2007, 13, 1066-1072.	2.0	40
378	Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy, 2007, 9, 539-547.	0.3	51
379	Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal of Hematology, 2007, 86, 414-417.	0.7	55
380	IgG multiple myeloma presented with ulcerative pyoderma gangrenosum. Leukemia and Lymphoma, 2007, 48, 1420-1422.	0.6	8
381	Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib. Leukemia and Lymphoma, 2007, 48, 1015-1018.	0.6	6
382	An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2007, 48, 46-55.	0.6	50
383	Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2007, 48, 2345-2351.	0.6	40

#	Article	IF	Citations
384	Proteasome Inhibitors in the Clinical Setting. Drugs in R and D, 2007, 8, 1-12.	1.1	26
385	Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. Cytotherapy, 2007, 9, 548-554.	0.3	19
386	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings, 2007, 82, 1179-1184.	1.4	142
387	Role of Stem Cell Transplantation. Hematology/Oncology Clinics of North America, 2007, 21, 1157-1174.	0.9	22
388	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. New England Journal of Medicine, 2007, 357, 2133-2142.	13.9	1,186
389	Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood, 2007, 109, 2100-2105.	0.6	117
391	Repeated Complete Responses with Bortezomib in a Heavily Pretreated Primary Refractory Patient with Light Chain Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 373-375.	1.4	5
392	Current Treatment Strategies for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S139-S144.	1.4	8
393	Preclinical Rationale, Mechanisms of Action, and Clinical Activity of Anthracyclines in Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S145-S149.	1.4	5
394	Role of autologous stem-cell transplantation in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 747-759.	0.7	25
395	Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Practice and Research in Clinical Haematology, 2007, 20, 665-680.	0.7	42
396	Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica, 2007, 92, 928-935.	1.7	73
397	Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems. Haematologica, 2007, 92, 110-114.	1.7	23
399	Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. The Korean Journal of Hematology, 2007, 42, 276.	0.7	0
400	O valor da imunofenotipagem para o diagnÃ³stico do Mieloma MÃºltiplo e na avaliaÃ§Ã£o da doenÃ§a residual mÃnima. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
401	Current status and future directions in the treatment of multiple myeloma. Chinese Medical Journal, 2007, 120, 1651-1654.	0.9	1
402	Community experience with bortezomib in patients with multiple myeloma. American Journal of Hematology, 2007, 82, 637-639.	2.0	6
403	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. American Journal of Hematology, 2007, 82, 831-833.	2.0	34

#	Article	IF	Citations
404	Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. American Journal of Hematology, 2007, 82, 1071-1075.	2.0	15
405	Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and) Tj ETQq1 1 0.784314 rgBT /Over		
406	The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer, 2007, 109, 1617-1626.	2.0	75
407	Epidemiology of multiple myeloma in Taiwan. Cancer, 2007, 110, 896-905.	2.0	92
408	Time to first disease progression, but not Î²2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer, 2007, 110, 824-829.	2.0	19
409	High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leukemia Research, 2007, 31, 1069-1075.	0.4	32
410	High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leukemia Research, 2007, 31, 1063-1068.	0.4	4
411	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 279-283.	1.3	41
412	Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2007, 39, 389-396.	1.3	37
413	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 605-611.	1.3	57
414	Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplantation, 2007, 40, 355-359.	1.3	23
415	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplantation, 2007, 40, 1101-1114.	1.3	27
416	The evolving background for high-dose treatment for myeloma. Bone Marrow Transplantation, 2007, 40, 1097-1100.	1.3	5
417	Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia, 2007, 21, 164-168.	3.3	113
418	Rituximab in CD20 positive multiple myeloma. Leukemia, 2007, 21, 835-836.	3.3	53
419	Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide. Leukemia, 2007, 21, 818-820.	3.3	6
420	Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal, 2007, 37, 456-463.	0.5	26
421	Bortezomib-associated rash: a new recognizable and avoidable side-effect. British Journal of Dermatology, 2007, 156, 784-785.	1.4	17

#	Article	IF	Citations
422	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	1.2	63
423	Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. British Journal of Haematology, 2007, 136, 729-735.	1.2	32
424	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. British Journal of Haematology, 2007, 137, 268-269.	1.2	96
425	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. British Journal of Haematology, 2007, 137, 429-435.	1.2	115
426	Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. British Journal of Haematology, 2007, 137, 530-536.	1.2	44
427	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 2007, 138, 176-185.	1.2	304
428	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 2007, 138, 330-337.	1.2	156
429	Thalidomide maintenance following highâ€dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. British Journal of Haematology, 2007, 139, 429-433.	1.2	35
430	InÂvivoandinÂsilicostudies on single versus multiple transplants for multiple myeloma. Cancer Science, 2007, 98, 734-739.	1.7	6
431	Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Science, 2007, 98, 1035-1040.	1.7	15
432	Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Science, 2007, 99, 071029014002001-???.	1.7	51
433	Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. European Journal of Haematology, 2007, 78, 35-40.	1.1	16
434	Thalidomide?dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide?dexamethasone: a case-matched study in advanced multiple myeloma. European Journal of Haematology, 2007, 78, 297-302.	1.1	30
435	Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. European Journal of Haematology, 2007, 79, 93-99.	1.1	13
436	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology, 2007, 79, 305-309.	1.1	9
437	Effect of CD34+cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. European Journal of Haematology, 2007, 78, 21-28.	1.1	58
438	Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology, 2007, 24, 227-230.	1.2	106
440	Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology, 2007, 86, 211-216.	0.8	43

#	Article	IF	Citations
441	Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of Hematology, 2007, 86, 583-589.	0.8	12
442	Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. Annals of Hematology, 2007, 86, 575-581.	0.8	5
443	O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemotherapy and Pharmacology, 2007, 60, 415-421.	1.1	25
444	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. International Journal of Clinical Oncology, 2007, 12, 318-326.	1.0	42
445	In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2007, 20, 93-101.	1.1	25
446	Current status of bortezomib in the treatment of multiple myeloma. Current Hematologic Malignancy Reports, 2007, 2, 128-137.	1.2	9
447	Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology, 2008, 87, 623-631.	0.8	38
448	Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. International Journal of Hematology, 2008, 88, 396-402.	0.7	11
449	Long-term survival in multiple myeloma: a single-center experience. Clinical and Experimental Medicine, 2008, 8, 133-139.	1.9	6
451	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 2008, 112, 1529-1537.	2.0	68
452	Highâ€dose melphalanâ€based autotransplants for multiple myeloma. Cancer, 2008, 112, 1754-1764.	2.0	15
453	Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma. Cancer, 2008, 112, 2720-2725.	2.0	13
454	Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 2008, 113, 355-359.	2.0	115
455	The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. American Journal of Hematology, 2008, 83, 355-358.	2.0	41
456	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	2.0	123
457	Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Research, 2008, 32, 1295-1298.	0.4	12
458	Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leukemia Research, 2008, 32, 1078-1084.	0.4	65
459	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	0.8	263

#	Article	IF	Citations
460	Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 2008, 22, 1250-1255.	3.3	79
461	VTD combination therapy with bortezomibâ€"thalidomideâ€"dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, 2008, 22, 1419-1427.	3.3	129
462	Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplantation, 2008, 42, 259-264.	1.3	10
463	High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplantation, 2008, 42, 405-412.	1.3	55
464	Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplantation, 2008, 41, 953-960.	1.3	62
465	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplantation, 2008, 41, 1013-1019.	1.3	20
466	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation, 2008, 41, 51-54.	1.3	19
467	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplantation, 2008, 41, 779-784.	1.3	44
468	Clinically relevant end points and new drug approvals for myeloma. Leukemia, 2008, 22, 231-239.	3.3	192
469	Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia, 2008, 22, 842-849.	3.3	163
470	Position statement on the use of bortezomib in multiple myeloma. International Journal of Laboratory Hematology, 2008, 30, 1-10.	0.7	15
471	Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology, 2008, 140, 625-634.	1.2	156
472	Should prophylactic granulocyteâ€colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomideâ€based therapy?. British Journal of Haematology, 2008, 140, 324-326.	1.2	16
473	Bortezomib, doxorubicin and dexamethasone (PAD) frontâ€line treatment of multiple myeloma: updated results after longâ€term followâ€up. British Journal of Haematology, 2008, 141, 512-516.	1.2	125
474	Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. British Journal of Haematology, 2008, 141, 41-51.	1.2	118
475	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. British Journal of Haematology, 2008, 141, 205-211.	1.2	20
476	Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stemâ€cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology, 2008, 143, 191-200.	1.2	78
477	The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British Journal of Haematology, 2008, 141, 814-819.	1.2	40

#	Article	IF	Citations
478	Evaluation of minimal residual disease in multiple myeloma patients by fluorescentâ€polymerase chain reaction: the prognostic impact of achieving molecular response. British Journal of Haematology, 2008, 142, 766-774.	1.2	52
479	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 2008, 143, 46-53.	1.2	94
480	Infusion of haploâ€identical killer immunoglobulinâ€like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. British Journal of Haematology, 2008, 143, 641-653.	1.2	175
481	Updated survival analyses after prolonged followâ€up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology, 2008, 143, 537-540.	1.2	84
482	Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British Journal of Haematology, 2008, 143, 654-660.	1.2	43
483	Lenalidomide in the treatment of multiple myeloma: a review. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 219-226.	0.7	70
485	High serum YKLâ€40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. European Journal of Haematology, 2008, 80, 310-317.	1.1	18
486	Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DTâ€PACE. European Journal of Haematology, 2008, 81, 432-436.	1.1	16
487	An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 140-145.	1.4	44
488	Thalidomide Maintenance Following High-Dose Melphalan with Autologous Stem Cell Support in Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 153-158.	1.4	7
489	Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 237-240.	1.4	59
490	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54
493	Bortezomib as an Alternative in the Treatment of Patients With Malignant Gammopathy. Farmacia Hospitalaria (English Edition), 2008, 32, 280-285.	0.0	1
494	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	13.9	1,787
495	The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2008, 17, 879-895.	1.9	112
496	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, 2008, 112, 4445-4451.	0.6	164
497	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. Journal of Heart and Lung Transplantation, 2008, 27, 823-829.	0.3	117
498	Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 116-124.	2.0	79

#	Article	IF	Citations
499	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biology of Blood and Marrow Transplantation, 2008, 14, 1401-1407.	2.0	39
500	A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treatment Reviews, 2008, 34, 442-452.	3.4	71
501	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	1.4	41
502	In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved. Biology of Blood and Marrow Transplantation, 2008, 14, 709-718.	2.0	1
503	The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 2008, 10, 507-517.	0.3	20
505	Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia and Lymphoma, 2008, 49, 298-305.	0.6	32
506	Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. Leukemia and Lymphoma, 2008, 49, 306-314.	0.6	26
507	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	0.6	74
508	Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. Journal of Clinical Oncology, 2008, 26, 480-492.	0.8	55
509	Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1156-62.	1.4	7
510	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. Journal of Clinical Oncology, 2008, 26, 2737-2744.	0.8	193
511	Induction Therapy in Multiple Myeloma. Hematology American Society of Hematology Education Program, 2008, 2008, 306-312.	0.9	26
512	Bortezomib in multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 639-654.	1.5	22
513	Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 4777-4783.	0.8	100
514	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 2171-2177.	0.8	322
515	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia and Lymphoma, 2008, 49, 502-507.	0.6	185
516	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 5904-5909.	0.8	139
517	Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. Journal of the National Cancer Institute, 2008, 100, 373-373.	3.0	7

#	Article	IF	Citations
518	Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. American Journal of Health-System Pharmacy, 2008, 65, 1221-1231.	0.5	48
519	Multiple Myeloma Cancer Stem Cells. Journal of Clinical Oncology, 2008, 26, 2895-2900.	0.8	101
520	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Antiâ€“Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	0.8	152
521	Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy. Oncologist, 2008, 13, 1120-1127.	1.9	34
522	Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 2008, 93, 124-127.	1.7	136
523	Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood, 2008, 111, 1805-1810.	0.6	119
524	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica, 2008, 93, 560-565.	1.7	82
525	BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood, 2008, 111, 1101-1109.	0.6	175
526	Appraisal of immunoglobulin free light chain as a marker of response. Blood, 2008, 111, 4908-4915.	0.6	121
527	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood, 2008, 112, 3591-3593.	0.6	247
528	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, 112, 3107-3114.	0.6	339
529	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008, 112, 3122-3125.	0.6	90
530	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 2008, 112, 4017-4023.	0.6	425
531	High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica, 2008, 93, 455-458.	1.7	61
532	Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica, 2008, 93, 295-298.	1.7	115
533	Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica, 2008, 93, 1908-1911.	1.7	111
534	AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA. , 0, , 86-100.		0
535	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 2008, 93, 1343-1350.	1.7	18

#	Article	IF	Citations
536	Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience. Journal of Korean Medical Science, 2008, 23, 819.	1.1	16
537	Bortezomib Therapy Followed by Autologous Stem Cell Transplantation in POEMS Syndrome. The Korean Journal of Hematology, 2008, 43, 145.	0.7	1
538	Comparison between Conventional Cytogenetics and Interphase Fluorescence in situ Hybridization (FISH) for Patients with Multiple Myeloma. The Korean Journal of Hematology, 2009, 44, 14.	0.7	2
539	Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Therapeutics and Clinical Risk Management, 2009, 5, 151.	0.9	14
540	A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 2009, 15, 1069-1075.	3.2	40
541	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5713-5719.	0.8	155
542	Serum Free Light Chain Ratio, Total Î¹/Î» Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clinical Chemistry, 2009, 55, 1510-1516.	1.5	33
543	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. Acta Haematologica, 2009, 122, 39-41.	0.7	2
544	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5001-5007.	0.8	46
545	The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. Journal of Clinical Pathology, 2009, 62, 1009-1015.	1.0	19
546	Pathologic Fractures in Patients With Multiple Myeloma Undergoing Bisphosphonate Therapy: Incidence and Correlation With Course of Disease. American Journal of Roentgenology, 2009, 193, 656-661.	1.0	18
547	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology, 2009, 27, 3518-3525.	0.8	241
548	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. Journal of Clinical Oncology, 2009, 27, 6086-6093.	0.8	154
549	Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204). Journal of Clinical Oncology, 2009, 27, 3510-3517.	0.8	21
550	Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2009, 27, 5015-5022.	0.8	74
551	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica, 2009, 94, 372-379.	1.7	60
552	Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma. Clinical Cancer Research, 2009, 15, 1343-1352.	3.2	70
553	Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma. Japanese Journal of Clinical Oncology, 2009, 39, 449-455.	0.6	9

#	Article	IF	Citations
554	Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Medicine, 2009, 7, 44.	2.3	90
555	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	1.1	21
556	Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and wellâ€tolerated frontline regimen. European Journal of Haematology, 2009, 82, 433-439.	1.1	21
557	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology, 2009, 82, 426-432.	1.1	104
558	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Experimental Hematology, 2009, 37, 791-798.	0.2	90
559	Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after highâ€dose chemotherapy and autologous stem cell transplantation. American Journal of Hematology, 2009, 84, 283-286.	2.0	12
560	A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematological Oncology, 2009, 27, 17-22.	0.8	52
561	Novel agents in myeloma: An exciting saga. Cancer, 2009, 115, 236-242.	2.0	5
562	Multiple Myeloma. Current Problems in Cancer, 2009, 33, 7-64.	1.0	64
563	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. International Journal of Hematology, 2009, 89, 538-545.	0.7	8
564	Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. International Journal of Hematology, 2009, 90, 635-642.	0.7	11
565	Cutaneous involvement in multiple myeloma and bortezomib. Annals of Hematology, 2009, 88, 1137-1139.	0.8	4
566	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Annals of Hematology, 2009, 88, 1125-1130.	0.8	40
567	High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. British Journal of Haematology, 2009, 144, 169-175.	1.2	101
568	Bortezomib, lowâ€dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. British Journal of Haematology, 2009, 144, 887-894.	1.2	46
569	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€modification guideline. British Journal of Haematology, 2009, 144, 895-903.	1.2	289
570	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology, 2009, 145, 681-708.	1.2	31
571	Extended followâ€up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology, 2009, 146, 619-626.	1.2	58

#	Article	IF	Citations
572	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2009, 147, 531-534.	1.2	27
573	Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009, 23, 3-9.	3.3	1,000
574	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009, 23, 215-224.	3.3	686
575	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia, 2009, 23, 1716-1730.	3.3	136
576	Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 2009, 23, 2147-2152.	3.3	350
577	The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia, 2009, 23, 2222-2232.	3.3	75
578	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 2009, 23, 1337-1341.	3.3	347
579	Is the international staging system superior to the Durieâ€“Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia, 2009, 23, 1528-1534.	3.3	81
580	High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplantation, 2009, 43, 481-489.	1.3	19
581	Outcomes after auto-SCT in African Americans with multiple myeloma. Bone Marrow Transplantation, 2009, 43, 845-851.	1.3	4
582	BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2009, 44, 157-161.	1.3	17
583	Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene, 2009, 28, 3866-3879.	2.6	71
584	Atacicept in relapsed/refractory multiple myeloma or active WaldenstrÃ¶m's macroglobulinemia: a phase I study. British Journal of Cancer, 2009, 101, 1051-1058.	2.9	71
585	High complete remission rate and durable remissions achieved with rational use of autologous stemâ€cell transplantation, thalidomide maintenance, and nonâ€myeloablative allogeneic transplantation in patients with multiple myeloma. Clinical Transplantation, 2009, 23, 839-847.	0.8	2
586	Elucidation of potential bortezomib response markers in mutliple myeloma patients. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 115-122.	1.4	17
587	Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research, 2009, 33, 1475-1480.	0.4	75
588	Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leukemia Research, 2009, 33, 1615-1618.	0.4	14
589	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 2009, 27, 5720-5726.	0.8	155

#	Article	IF	Citations
590	The impact of extramedullary disease at presentation on the outcome of myeloma. Leukemia and Lymphoma, 2009, 50, 230-235.	0.6	97
591	Imaging patients with myeloma. Clinical Radiology, 2009, 64, 1-11.	0.5	51
592	Whole-body MRI of multiple myeloma: Comparison of different MRI sequences in assessment of different growth patterns. European Journal of Radiology, 2009, 69, 339-345.	1.2	40
593	A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biology of Blood and Marrow Transplantation, 2009, 15, 83-91.	2.0	27
594	Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 463-470.	2.0	55
595	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 812-816.	2.0	68
596	Triple MEL100 Therapy in Multiple Myeloma. Transplantation Proceedings, 2009, 41, 3863-3867.	0.3	1
597	Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment. Clinical Lymphoma and Myeloma, 2009, 9, 394-398.	1.4	26
598	Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant. Biology of Blood and Marrow Transplantation, 2009, 15, 686-693.	2.0	24
599	A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies. Clinical Cancer Research, 2009, 15, 7085-7091.	3.2	269
600	Bortezomib. Drugs, 2009, 69, 859-888.	4.9	138
601	Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. Clinical Lymphoma and Myeloma, 2009, 9, 145-150.	1.4	36
602	Thrombopoietic Cytokine and P-Selectin Levels in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Decrease in Posttransplantation P-Selectin Levels Might Predict the Degree of Maximum Response. Clinical Lymphoma and Myeloma, 2009, 9, 229-233.	1.4	5
603	Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse. Clinical Lymphoma and Myeloma, 2009, 9, 436-442.	1.4	11
604	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. Journal of Clinical Oncology, 2009, 27, 1788-1793.	0.8	315
605	Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia and Lymphoma, 2009, 50, 559-565.	0.6	66
606	Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leukemia and Lymphoma, 2009, 50, 1442-1447.	0.6	41
607	Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma, 2009, 50, 223-229.	0.6	9

#	Article	IF	Citations
608	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia and Lymphoma, 2009, 50, 216-222.	0.6	24
609	Dasatinib in relapsed or plateau-phase multiple myeloma. Leukemia and Lymphoma, 2009, 50, 137-140.	0.6	17
610	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood, 2009, 114, 4369-4372.	0.6	67
611	The role of complete response in multiple myeloma. Blood, 2009, 114, 3139-3146.	0.6	206
612	Multiple myeloma. Lancet, The, 2009, 374, 324-339.	6.3	685
613	The Importance of Complete Response in Outcomes in Myeloma. Cancer Journal (Sudbury, Mass), 2009, 15, 465-472.	1.0	9
614	Integrating Novel Therapies in the Transplant Paradigm. Cancer Journal (Sudbury, Mass), 2009, 15, 479-484.	1.0	3
615	F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 2009, 114, 2068-2076.	0.6	463
616	Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood, 2009, 114, 4954-4956.	0.6	60
617	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 2009, 113, 3435-3442.	0.6	213
618	Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood, 2009, 113, 4331-4340.	0.6	97
619	Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples) Tj ETQq1 1 0.784314 rgBT /O	0.6	119
620	Induction of angiogenesis by normal and malignant plasma cells. Blood, 2009, 114, 128-143.	0.6	127
621	Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood, 2009, 114, 522-525.	0.6	178
622	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 2009, 114, 772-778.	0.6	145
623	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood, 2009, 114, 2617-2618.	0.6	45
624	The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood, 2009, 114, 38-39.	0.6	42
625	Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood, 2009, 114, 1299-1305.	0.6	92

#	Article	IF	Citations
626	Bendamustine in patients with relapsed or refractory multiple myeloma. European Journal of Medical Research, 2010, 15, 13.	0.9	34
627	Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica, 2010, 95, 804-809.	1.7	86
628	Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica, 2010, 95, 1548-1554.	1.7	75
629	Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica, 2010, 95, 1738-1744.	1.7	109
630	A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica, 2010, 95, 845-848.	1.7	129
631	A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood, 2010, 115, 1113-1120.	0.6	271
632	Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. Blood, 2010, 115, 3413-3414.	0.6	7
633	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, 2010, 116, 1220-1227.	0.6	100
634	Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 2010, 115, 3416-3417.	0.6	179
635	Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood, 2010, 116, 2033-2039.	0.6	43
636	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood, 2010, 116, 3743-3750.	0.6	101
637	Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. European Radiology, 2010, 20, 2899-2906.	2.3	18
638	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. Journal of Clinical Oncology, 2010, 28, 2259-2266.	0.8	403
639	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology, 2010, 89, 185-190.	0.8	99
640	Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8Âyears. Annals of Hematology, 2010, 89, 291-297.	0.8	23
641	Salvage treatment with upfront melphalan 100Âmg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma. Annals of Hematology, 2010, 89, 483-487.	0.8	6
642	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology, 2010, 89, 489-497.	0.8	12
643	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology, 2010, 89, 905-912.	0.8	17

#	Article	IF	Citations
644	A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Annals of Hematology, 2010, 89, 1019-1027.	0.8	15
645	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology, 2010, 89, 1133-1140.	0.8	54
646	Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. International Journal of Hematology, 2010, 92, 118-126.	0.7	42
647	Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. International Journal of Hematology, 2010, 92, 518-523.	0.7	6
648	The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology, 2010, 38, 860-867.	0.2	72
649	Safety and efficacy of bortezomibâ€based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology, 2010, 84, 223-228.	1.1	77
650	ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European Journal of Haematology, 2010, 84, 474-483.	1.1	20
651	Depth of response assessed by quantitative ASOâ€PCR predicts the outcome after stem cell transplantation in multiple myeloma. European Journal of Haematology, 2010, 85, 416-423.	1.1	43
652	Residual serum monoclonal protein predicts progressionâ€free survival in patients with previously untreated multiple myeloma. Cancer, 2010, 116, 640-646.	2.0	3
653	The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 2010, 116, 3807-3814.	2.0	118
654	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer, 2010, 116, 3143-3151.	2.0	32
655	Allogenic hematopoietic stemâ€cell transplantation with reducedâ€intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer, 2010, 116, 3621-3630.	2.0	44
656	Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2010, 78B, 338-347.	0.7	28
657	A Phase II study of ¹⁵³Smâ€EDTMP and highâ€dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. American Journal of Hematology, 2010, 85, 409-413.	2.0	22
658	Longâ€term results of singleâ€agent thalidomide as initial therapy for asymptomatic (smoldering or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	24
659	Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China. Anatomical Record, 2010, 293, 1679-1684.	0.8	7
660	Role of the TNF-Î± promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leukemia Research, 2010, 34, 1453-1458.	0.4	27
661	The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Group. Leukemia Research, 2010, 34, 1330-1335.	0.4	14

#	Article	IF	Citations
662	Standardâ€•versus highâ€dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. Transfusion, 2010, 50, 2432-2446.	0.8	14
663	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	1.1	66
664	Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasoneâ€refractory myeloma. British Journal of Haematology, 2010, 148, 335-337.	1.2	27
665	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. British Journal of Haematology, 2010, 148, 323-331.	1.2	55
666	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. British Journal of Haematology, 2010, 149, 334-351.	1.2	88
667	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology, 2010, 150, 428-437.	1.2	65
668	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 doseâ€escalation study. British Journal of Haematology, 2010, 150, 438-445.	1.2	62
669	Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamÃ©thasone. Leukemia, 2010, 24, 623-628.	3.3	130
670	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia, 2010, 24, 1406-1411.	3.3	44
671	Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells. Bone Marrow Transplantation, 2010, 45, 349-353.	1.3	97
672	CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation, 2010, 45, 498-504.	1.3	46
673	Plasma cell neoplasms. , 0, , 244-265.		0
674	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1422-1428.	0.8	150
675	How to Treat Multiple Myeloma: Thoughts on a Multicentre Survey in Germany. Onkologie, 2010, 33, 577-578.	1.1	0
676	Multiple myeloma. Annals of Oncology, 2010, 21, vii313-vii319.	0.6	37
677	Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents. Journal of Clinical Oncology, 2010, 28, 2612-2624.	0.8	186
678	Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia and Lymphoma, 2010, 51, 243-251.	0.6	15
679	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116, 679-686.	0.6	790

#	Article	IF	Citations
680	Monitoring Residual Myeloma. American Journal of Clinical Pathology, 2010, 134, 139-145.	0.4	10
681	Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 3015-3022.	0.8	181
682	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2010, 16, 3260-3269.	3.2	62
683	Is there a role for 'modified VAD' in the treatment of multiple myeloma?. Ecancermedicalscience, 2010, 3, 136.	0.6	0
684	Rapid control of previously untreated multiple myeloma with bortezomibâ€“lenalidomideâ€“dexamethasone (BLD). Hematology, 2010, 15, 70-73.	0.7	17
685	Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 2010, 21, 325-330.	0.6	386
686	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica, 2010, 95, 1144-1149.	1.7	40
687	Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias. , 2010, , 15-62.		3
688	Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagnostic Pathology, 2010, 5, 30.	0.9	34
689	Prediction of Response and Progression in Multiple Myeloma With Serum Free Light Chains Assay: Corroboration of the Serum Free Light Chain Response Definitions. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, E10-E13.	0.2	6
690	Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 138-143.	0.2	18
691	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 353-360.	0.2	4
692	Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 424-442.	0.2	26
693	Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 395-402.	2.0	55
695	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, The, 2010, 376, 2075-2085.	6.3	770
696	Role of new treatment approaches in defining treatment goals in multiple myeloma â€“ the ultimate goal is extended survival. Cancer Treatment Reviews, 2010, 36, S18-S23.	3.4	30
697	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 458-463.	0.2	29
698	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, The, 2010, 11, 29-37.	5.1	882

#	Article	IF	Citations
699	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncology, The, 2010, 11, 934-941.	5.1	427
700	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4621-4629.	0.8	512
701	Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leukemia and Lymphoma, 2010, 51, 2084-2091.	0.6	34
702	Response Assessment in Patients with Multiple Myeloma during Antiangiogenic Therapy using Arterial Spin Labeling and Diffusion-Weighted Imaging. Academic Radiology, 2010, 17, 1326-1333.	1.3	34
703	Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leukemia and Lymphoma, 2010, 51, 1577-1579.	0.6	19
704	Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study. Journal of Clinical Oncology, 2010, 28, 3160-3166.	0.8	263
705	Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leukemia and Lymphoma, 2011, 52, 1281-1289.	0.6	7
706	Managing multiple myeloma in the elderly: are we making progress?. Expert Review of Hematology, 2011, 4, 301-315.	1.0	6
707	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. Journal of Clinical Oncology, 2011, 29, 1898-1906.	0.8	126
708	Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. Journal of Medical Economics, 2011, 14, 690-697.	1.0	29
709	Multiple Myeloma. Annual Review of Medicine, 2011, 62, 249-264.	5.0	121
710	Lenalidomide. Drugs, 2011, 71, 625-649.	4.9	24
711	Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-HodgkinÊ¼s Lymphoma. Clinical Pharmacokinetics, 2011, 50, 781-791.	1.6	31
712	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 38-43.	0.2	59
713	Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leukemia and Lymphoma, 2011, 52, 1271-1280.	0.6	18
714	Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leukemia and Lymphoma, 2011, 52, 1455-1462.	0.6	55
715	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 412-420.	2.0	40
716	Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional Morphology on Disease Progression. Biology of Blood and Marrow Transplantation, 2011, 17, 1084-1087.	2.0	7

#	Article	IF	Citations
717	Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2011, 17, 1765-1774.	2.0	53
718	Artificial Scaffolds and Mesenchymal Stem Cells for Hard Tissues. Advances in Biochemical Engineering/Biotechnology, 2011, 126, 153-194.	0.6	11
719	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, 1627-1633.	0.8	202
720	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncology, The, 2011, 12, 431-440.	5.1	835
721	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica, 2011, 96, 1504-1511.	1.7	48
722	Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines. PLoS ONE, 2011, 6, e19322.	1.1	18
723	Lenalidomide: from relapsed/refractory multiple myeloma to upfront therapy. Aging Health, 2011, 7, 665-676.	0.3	0
724	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood, 2011, 118, 6274-6283.	0.6	83
725	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 2011, 117, 3041-3044.	0.6	109
726	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood, 2011, 117, 3025-3031.	0.6	247
727	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
728	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood, 2011, 118, 529-534.	0.6	183
729	Toward deeper response in MM. Blood, 2011, 117, 2986-2987.	0.6	2
730	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood, 2011, 118, 535-543.	0.6	82
731	Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood, 2011, 118, 2702-2707.	0.6	23
732	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood, 2011, 118, 4547-4553.	0.6	53
733	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 2011, 118, 2413-2419.	0.6	174
734	Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood, 2011, 118, 5901-5904.	0.6	63

#	Article	IF	Citations
735	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood, 2011, 118, 5989-5995.	0.6	445
736	Polymorphisms of nuclear factor-ÂB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica, 2011, 96, 729-737.	1.7	46
737	A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica, 2011, 96, 333-336.	1.7	52
738	Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica, 2011, 96, 171-173.	1.7	38
739	Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. British Journal of Haematology, 2011, 152, 108-110.	1.2	8
740	Characterization of haematological parameters with bortezomibâ€“melphalanâ€“prednisone versus melphalanâ€“prednisone in newly diagnosed myeloma, with evaluation of longâ€term outcomes and risk of thromboembolic events with use of erythropoiesisâ€stimulating agents: analysis of the VISTA trial. British Journal of Haematology, 2011, 153, 212-221.	1.2	13
741	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	1.2	252
742	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology, 2011, 153, 729-740.	1.2	102
743	Excess bone marrow Bâ€cells in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation is a biomarker for improved survival. British Journal of Haematology, 2011, 155, 509-511.	1.2	5
744	A steroidâ€independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British Journal of Haematology, 2011, 154, 104-110.	1.2	11
745	Impact of highâ€risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. British Journal of Haematology, 2011, 155, 340-348.	1.2	29
746	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology, 2011, 155, 580-587.	1.2	29
747	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 2011, 86, 23-31.	1.1	126
748	Targeted idiotypeâ€fusion DNA vaccines for human multiple myeloma: preclinical testing. European Journal of Haematology, 2011, 86, 385-395.	1.1	10
749	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalanâ€“prednisone vs. melphalanâ€“prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
750	Paraprotein-related renal disease and amyloid. Medicine, 2011, 39, 481-485.	0.2	0
751	Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leukemia Research, 2011, 35, 1178-1183.	0.4	26
752	Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1046-1053.	3.3	79

#	Article	IF	Citations
753	Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunology, Immunotherapy, 2011, 60, 161-171.	2.0	67
754	A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Annals of Hematology, 2011, 90, 193-200.	0.8	18
755	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals of Hematology, 2011, 90, 429-439.	0.8	60
756	Autologous hematopoietic stem cell transplantationâ€"what determines the outcome: an experience from North India. Annals of Hematology, 2011, 90, 1317-1328.	0.8	10
757	Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Annals of Hematology, 2011, 90, 1441-1447.	0.8	4
758	Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 2011, 67, 57-67.	1.1	97
759	Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1439-1447.	1.1	41
760	Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone. International Journal of Hematology, 2011, 93, 59-65.	0.7	6
761	Changes in serumâ€free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology, 2011, 86, 251-255.	2.0	78
762	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	2.0	57
763	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer, 2011, 117, 336-342.	2.0	116
764	Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer, 2011, 117, 2136-2144.	2.0	54
765	Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leukemia Research, 2011, 35, 591-597.	0.4	13
766	An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy, 2011, 3, 1033-1040.	1.0	11
767	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia and Lymphoma, 2011, 52, 1942-1948.	0.6	28
768	Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica, 2011, 96, 87-95.	1.7	188
769	Melphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112. Japanese Journal of Clinical Oncology, 2011, 41, 586-589.	0.6	5
770	Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Annals of Oncology, 2011, 22, 411-416.	0.6	40

#	Article	IF	Citations
771	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research, 2011, 17, 3388-3397.	3.2	49
772	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Annals of Oncology, 2011, 22, 1628-1635.	0.6	65
773	Quality assessment, standardization. Clinical Chemistry and Laboratory Medicine, 2011, 49, .	1.4	1
774	Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood, 2011, 118, 1231-1238.	0.6	179
775	Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Japanese Journal of Clinical Oncology, 2011, 41, 353-357.	0.6	28
776	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. Journal of Clinical Oncology, 2011, 29, 3016-3022.	0.8	171
777	Treatment Options for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2011, 17, 1264-1277.	3.2	118
778	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomideâ€“CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2011, 29, 3427-3434.	0.8	77
779	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2011, 52, 2308-2315.	0.6	25
780	EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2011, 46, 676-681.	1.3	4
781	The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. Bone Marrow Transplantation, 2011, 46, 1210-1218.	1.3	7
782	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. Journal of Clinical Oncology, 2011, 29, 4243-4249.	0.8	118
784	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 2012, 49, 242-256.	0.8	71
785	Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. Bone Marrow Transplantation, 2012, 47, 1248-1249.	1.3	6
786	Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1174-1182.	0.6	19
787	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica, 2012, 97, 1925-1928.	1.7	119
788	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research, 2012, 18, 4830-4840.	3.2	128
789	Assessing response of myeloma bone disease with diffusion-weighted MRI. British Journal of Radiology, 2012, 85, e1198-e1203.	1.0	128

#	Article	IF	Citations
790	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 2012, 97, 64-72.	1.7	109
791	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation, 2012, 47, 831-837.	1.3	31
792	Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia, 2012, 26, 2398-2405.	3.3	66
793	Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. Journal of Clinical Pathology, 2012, 65, 823-829.	1.0	49
794	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2475-2482.	0.8	185
795	A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia, 2012, 26, 1675-1680.	3.3	37
796	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia and Lymphoma, 2012, 53, 275-281.	0.6	13
797	Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. OncoTargets and Therapy, 2012, 5, 329.	1.0	23
798	The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma. International Journal of Molecular Imaging, 2012, 2012, 1-6.	1.3	21
799	Curability of Multiple Myeloma. Bone Marrow Research, 2012, 2012, 1-5.	1.7	23
800	A simplified method for autologous stem cell transplantation in multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 49-53.	0.6	22
801	Attainment of a Stringent Complete Response in Multiple Myeloma with Thalidomide Monotherapy. Internal Medicine, 2012, 51, 2781-2783.	0.3	2
802	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica, 2012, 97, 784-791.	1.7	49
803	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica, 2012, 97, 616-621.	1.7	19
804	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica, 2012, 97, 442-450.	1.7	144
805	The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 2012, 119, 7-15.	0.6	315
806	Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood, 2012, 119, 4608-4613.	0.6	111
807	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 2012, 120, 9-19.	0.6	305

#	Article	IF	Citations
808	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood, 2012, 119, 5661-5670.	0.6	235
809	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, 120, 1801-1809.	0.6	393
810	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 2012, 120, 2817-2825.	0.6	608
811	Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance. Seminars in Hematology, 2012, 49, S3-S15.	1.8	10
812	An openâ€label, singleâ€arm, phase 2 study of singleâ€agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology, 2012, 158, 739-748.	1.2	157
813	A phase 1 study of lucatumumab, a fully human antiâ€<scp>CD</scp>40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2012, 159, 58-66.	1.2	101
814	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	0.6	429
815	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. Journal of Clinical Oncology, 2012, 30, 2946-2955.	0.8	735
816	Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. European Radiology, 2012, 22, 2007-2012.	2.3	58
817	Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: a longitudinal cohort study. Supportive Care in Cancer, 2012, 20, 2969-2975.	1.0	3
819	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 310-318.	0.2	104
820	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 2012, 30, 1960-1965.	0.8	184
821	Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leukemia and Lymphoma, 2012, 53, 1714-1721.	0.6	29
822	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood, 2012, 120, 2581-2588.	0.6	148
823	Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukemia and Lymphoma, 2012, 53, 632-634.	0.6	41
824	Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival. Biology of Blood and Marrow Transplantation, 2012, 18, 773-779.	2.0	108
825	Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous StemÂCell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1076-1079.	2.0	29
826	Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R) Tj ETQq1 1 0.784314 rgBT /Overlo		

#	Article	IF	Citations
827	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. Journal of Hematology and Oncology, 2012, 5, 28.	6.9	13
828	Development and validation of a PCRâ€based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. British Journal of Clinical Pharmacology, 2012, 74, 842-853.	1.1	10
829	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
830	First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. The Cochrane Library, 2012, 10, CD004626.	1.5	24
831	Prognostic Risk Factor Evaluation in Patients With Relapsed or Refractory Multiple Myeloma Receiving Lenalidomide Treatment: Analysis of Renal Function by eGFR and of Additional Comorbidities by Comorbidity Appraisal. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 38-48.	0.2	26
832	Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 118-126.	0.2	2
833	Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 319-324.	0.2	45
834	Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients. The Journal of Supportive Oncology, 2012, 10, 155-159.	2.3	32
835	Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. International Journal of Hematology, 2012, 96, 477-484.	0.7	1
836	Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 641-647.	0.6	34
837	Myeloma and Leukemia. , 2012, , 509-529.		1
838	Clinical and prognostic role of annexin A2 in multiple myeloma. Blood, 2012, 120, 1087-1094.	0.6	81
839	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1820-1823.	0.6	109
840	Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging, 2012, 12, 212-224.	1.2	9
841	Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Cancer Research, 2012, 18, 3697-3704.	3.2	54
842	Novel agentsâ€based regimens as induction treatment prior to autologous stemâ€cell transplantation in newly diagnosed multiple myeloma: a metaâ€analysis of randomized controlled trials. Hematological Oncology, 2012, 30, 57-61.	0.8	13
843	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematological Oncology, 2012, 30, 156-162.	0.8	10
844	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	13.9	1,024

#	Article	IF	Citations
845	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progressionâ€free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
846	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1759-1769.	13.9	692
847	Continuous treatment with lenalidomide in multiple myeloma: a case report. Memo - Magazine of European Medical Oncology, 2012, 5, 23-26.	0.3	1
848	Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. Indian Journal of Hematology and Blood Transfusion, 2012, 28, 67-76.	0.3	3
849	Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment. Annals of Hematology, 2012, 91, 889-896.	0.8	8
850	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1405-1412.	1.2	41
851	Treatment of MM-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy. European Spine Journal, 2012, 21, 912-919.	1.0	22
852	Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. British Journal of Haematology, 2012, 156, 552-555.	1.2	33
853	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Experimental Hematology, 2012, 40, 521-527.	0.2	41
854	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal of Haematology, 2012, 89, 10-15.	1.1	28
855	Healthâ€related quality of life in elderly, newly diagnosed multiple myeloma patients treated with <scp>VMP</scp> vs. <scp>MP</scp>: results from the <scp>VISTA</scp> trial. European Journal of Haematology, 2012, 89, 16-27.	1.1	65
856	Effect of time to infusion of autologous stem cells (24 vs. 48Âh) after highâ€dose melphalan in patients with multiple myeloma. European Journal of Haematology, 2012, 89, 145-150.	1.1	10
857	Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis. Leukemia Research, 2012, 36, 1016-1021.	0.4	43
858	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. British Journal of Haematology, 2012, 157, 125-127.	1.2	8
859	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. British Journal of Haematology, 2012, 158, 472-480.	1.2	55
860	Improved response with postâ€<scp>ASCT</scp> consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. British Journal of Haematology, 2012, 158, 499-505.	1.2	6
861	18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 493-500.	3.3	66
862	Long-term results of thalidomide and dexamethasone (thalâ€“dex) as therapy of first relapse in multiple myeloma. Annals of Hematology, 2012, 91, 419-426.	0.8	11

#	Article	IF	Citations
863	A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response. Investigational New Drugs, 2012, 30, 714-722.	1.2	6
864	A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Journal of Hematology and Oncology, 2013, 6, 41.	6.9	41
865	Epigenetic inactivation of the MIR129-2 in hematological malignancies. Journal of Hematology and Oncology, 2013, 6, 16.	6.9	59
866	Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica, 2013, 98, 1142-1146.	1.7	42
867	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomideâ€“dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	0.8	10
868	Subcutaneous Bortezomib. Drugs, 2013, 73, 45-54.	4.9	15
869	Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2013, 48, 1395-1400.	1.3	37
870	Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 592-601.	0.8	5
871	Stem Cell Labeling and Tracking with Nanoparticles. Particle and Particle Systems Characterization, 2013, 30, 1006-1017.	1.2	31
872	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 2013, 19, 69-74.	2.0	60
873	Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologousâ€“Allogeneic Tandem Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 398-404.	2.0	85
874	Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy, 2013, 47, 56-62.	0.9	55
875	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Experimental Hematology, 2013, 41, 1008-1015.	0.2	19
876	Autologous retransplantation for patients with recurrent multiple myeloma. Cancer, 2013, 119, 2438-2446.	2.0	51
877	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 2013, 31, 3279-3287.	0.8	238
878	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 1055-1066.	5.1	710
879	Phase I / II study of bortezomibâ€melphalanâ€prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Science, 2013, 104, 912-919.	1.7	18
880	A phase 2 multicentre study of siltuximab, an antiâ€interleukinâ€6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2013, 161, 357-366.	1.2	138

#	Article	IF	Citations
881	WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cellâ€“depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood, 2013, 121, 308-317.	0.6	69
882	Complications and Special Presentations of Plasma Cell Myeloma. , 2013, , 665-680.		1
883	Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. European Radiology, 2013, 23, 570-578.	2.3	87
884	Postallograft lenalidomide induces strong NK cellâ€“mediated antimyeloma activity and risk for T cellâ€“mediated GvHD: Results from a phase I/II dose-finding study. Experimental Hematology, 2013, 41, 134-142.e3.	0.2	83
885	Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 19-24.	0.2	2
886	High Frequencies of Response After Limited Primary Therapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 119-122.	0.2	1
887	Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic Factors. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 32-41.	0.2	14
888	Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features. Leukemia Research, 2013, 37, 1089-1093.	0.4	33
889	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1615-1624.	2.0	99
890	Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a longâ€term followâ€up study. British Journal of Haematology, 2013, 160, 199-206.	1.2	13
891	Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2013, 160, 321-330.	1.2	48
892	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology and Oncology, 2013, 6, 2.	6.9	42
893	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 27, 780-791.	3.3	294
894	Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplantation, 2013, 48, 269-277.	1.3	13
895	Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leukemia Research, 2013, 37, 641-646.	0.4	17
896	The role of the ubiquitin proteasome system in lymphoma. Critical Reviews in Oncology/Hematology, 2013, 87, 306-322.	2.0	16
897	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, 27, 423-429.	3.3	137
898	Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology, 2013, 31, 2540-2547.	0.8	372

#	Article	IF	Citations
899	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 2013, 160, 649-659.	1.2	111
900	Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma. Oncology, 2013, 85, 223-227.	0.9	15
901	Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplantation, 2013, 48, 403-407.	1.3	45
902	Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplantation, 2013, 48, 1537-1542.	1.3	20
903	Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment. Clinical Cancer Research, 2013, 19, 6030-6038.	3.2	143
904	Continuous treatment with new agents for newly diagnosed multiple myeloma. Anti-Cancer Drugs, 2013, 24, 527-533.	0.7	10
905	Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clinical Cancer Research, 2013, 19, 2248-2256.	3.2	78
906	New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials. Journal of Comparative Effectiveness Research, 2013, 2, 469-481.	0.6	2
907	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2013, 6, 531.	1.0	30
908	A phase 2 study of <scp>SRT</scp>501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. British Journal of Haematology, 2013, 160, 714-717.	1.2	160
909	Phase <scp>II</scp> clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (<scp>RIC</scp>) and postâ€allogeneic transplantation for highâ€risk myeloma patients. British Journal of Haematology, 2013, 162, 474-482.	1.2	36
910	Role of Dynamic Contrastâ€Enhanced Sonography for Characterization and Monitoring of Extramedullary Myeloma. Journal of Ultrasound in Medicine, 2013, 32, 1777-1788.	0.8	0
911	Phase I, multicentre, doseâ€escalation trial of monotherapy with milatuzumab (humanized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 267 T Journal of Haematology, 2013, 163, 478-486.	1.2	89
912	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€<scp>PCR</scp> of immunoglobulin genes in multiple myeloma. Results from a <scp>GEM</scp>/<scp>PETHEMA</scp> study. British Journal of Haematology, 2013, 163, 581-589.	1.2	27
913	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 448-455.	0.8	250
914	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	0.8	147
915	Sorafenib in patients with refractory or recurrent multiple myeloma. Hematological Oncology, 2013, 31, 197-200.	0.8	30
916	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood, 2013, 121, 1961-1967.	0.6	152

#	Article	IF	Citations
917	A Phase I, Open-Label Study of Siltuximab, an Antiâ€“IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research, 2013, 19, 3659-3670.	3.2	180
918	Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia, 2013, 27, 213-219.	3.3	99
919	Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia, 2013, 27, 1707-1714.	3.3	140
920	Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia, 2013, 27, 2351-2356.	3.3	72
921	Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood, 2013, 121, 1819-1823.	0.6	181
922	A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood, 2013, 121, 1517-1523.	0.6	137
923	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood, 2013, 121, 4647-4654.	0.6	128
924	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013, 121, 5055-5063.	0.6	171
925	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood, 2013, 122, 2331-2337.	0.6	281
926	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	0.6	21
927	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, 122, 3122-3128.	0.6	126
928	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
929	Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Management and Research, 2013, 5, 37.	0.9	19
930	Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. PLoS ONE, 2013, 8, e83252.	1.1	13
931	Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. OncoTargets and Therapy, 2014, 7, 1593.	1.0	11
932	Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study. Human Vaccines and Immunotherapeutics, 2014, 10, 3394-3408.	1.4	14
933	Elotuzumab for the treatment of multiple myeloma. Future Oncology, 2014, 10, 949-956.	1.1	9
934	A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. Bone Marrow Transplantation, 2014, 49, 492-495.	1.3	16

#	Article	IF	Citations
935	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. Ca-A Cancer Journal for Clinicians, 2014, 64, 422-444.	157.7	85
936	Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplantation, 2014, 49, 422-425.	1.3	3
937	Association of response endpoints with survival outcomes in multiple myeloma. Leukemia, 2014, 28, 258-268.	3.3	128
938	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia, 2014, 28, 1529-1536.	3.3	61
939	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 2014, 124, 1038-1046.	0.6	192
940	The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients. BioMed Research International, 2014, 2014, 1-6.	0.9	3
941	Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. BioMed Research International, 2014, 2014, 1-7.	0.9	5
942	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380.	0.2	3
943	Allogeneic transplantation in multiple myeloma. Expert Review of Hematology, 2014, 7, 79-90.	1.0	13
944	Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. BioMed Research International, 2014, 2014, 1-8.	0.9	9
945	Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma â€“ a retrospective population based study of 1162 patients. European Journal of Haematology, 2014, 92, 19-25.	1.1	4
946	High incidence of postâ€transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomibâ€based regimens: a survey from the Rome Transplant Network. Transplant Infectious Disease, 2014, 16, 158-164.	0.7	38
947	Challenges faced by bone marrow registries in India. Indian Journal of Transplantation, 2014, 8, 80-83.	0.0	7
948	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. European Journal of Haematology, 2014, 92, 308-312.	1.1	31
949	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. British Journal of Haematology, 2014, 164, 684-693.	1.2	38
950	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. Lancet Haematology,the, 2014, 1, e112-e119.	2.2	8
951	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. British Journal of Haematology, 2014, 166, 401-409.	1.2	35
952	A multicenter, openâ€label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. American Journal of Hematology, 2014, 89, 1037-1042.	2.0	36

#	Article	IF	Citations
954	Cancerâ€“Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma. Cancer Immunology Research, 2014, 2, 547-558.	1.6	9
955	A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leukemia and Lymphoma, 2014, 55, 2013-2017.	0.6	15
956	Bone marrow megakaryocytes, soluble P-selectin and thrombopoietic cytokines in multiple myeloma patients. Platelets, 2014, 25, 181-187.	1.1	17
957	Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 81-98.	0.1	0
958	Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a singleâ€institution study. Transplant Infectious Disease, 2014, 16, 1032-1038.	0.7	17
959	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€œNonhybridâ€•(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research, 2014, 20, 5652-5662.	3.2	26
960	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. Biology of Blood and Marrow Transplantation, 2014, 20, 1026-1032.	2.0	28
961	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia, 2014, 28, 391-397.	3.3	155
962	â€œReal-worldâ€•data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of Hematology, 2014, 93, 129-139.	0.8	38
963	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Annals of Hematology, 2014, 93, 123-128.	0.8	15
964	How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 303-309.	1.2	10
965	BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Annals of Hematology, 2014, 93, 635-644.	0.8	46
966	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood, 2014, 123, 1461-1469.	0.6	174
967	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia, 2014, 28, 2075-2079.	3.3	57
968	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€matched study. American Journal of Hematology, 2014, 89, 355-362.	2.0	24
969	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, 2014, 123, 3414-3419.	0.6	68
970	Sotatercept in patients with osteolytic lesions of multiple myeloma. British Journal of Haematology, 2014, 165, 814-823.	1.2	105
971	Bortezomib-Cyclophosphamide-Dexamethasone (VCD)versusBortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. British Journal of Haematology, 2014, 166, 702-710.	1.2	45

#	Article	IF	Citations
972	International Myeloma Working Group recommendations for global myeloma care. Leukemia, 2014, 28, 981-992.	3.3	162
973	Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplantation, 2014, 49, 223-227.	1.3	29
974	Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2014, 93, 107-111.	0.8	5
975	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 587-600.	0.8	330
976	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research, 2014, 20, 804-813.	3.2	29
977	Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood, 2014, 123, 985-991.	0.6	92
978	Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Annals of Hematology, 2014, 93, 1993-1999.	0.8	10
979	Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer Journal, 2014, 4, e257-e257.	2.8	39
980	Bortezomibâ€“thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials. Leukemia Research, 2014, 38, 1048-1054.	0.4	14
981	Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia, 2014, 28, 2229-2234.	3.3	67
982	Bortezomibâ€•and thalidomideâ€‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American Journal of Hematology, 2014, 89, 1085-1091.	2.0	45
983	Complete response after autologous stem cell transplant in multiple myeloma. Cancer Medicine, 2014, 3, 939-946.	1.3	23
984	Controversies in Multiple Myeloma: to Transplant or Not?. Current Hematologic Malignancy Reports, 2014, 9, 360-367.	1.2	4
985	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology, 2014, 93, 89-98.	0.8	35
986	Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biology, 2014, 15, R47.	13.9	645
987	Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Japanese Journal of Clinical Oncology, 2014, 44, 435-441.	0.6	6
988	Response evaluation and monitoring of multiple myeloma. Expert Review of Hematology, 2014, 7, 33-42.	1.0	8
989	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695

#	Article	IF	Citations
990	Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 148-154.	0.2	13
991	Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 19-24.	0.7	9
992	Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leukemia Research, 2014, 38, 925-930.	0.4	21
993	Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. Leukemia Research, 2014, 38, 666-672.	0.4	1
994	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 2014, 123, 632-639.	0.6	98
995	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123, 1826-1832.	0.6	327
996	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (antiâ€“IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	0.6	125
997	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood, 2014, 124, 1047-1055.	0.6	185
998	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	0.6	380
999	A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, 124, 899-906.	0.6	73
1000	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, 99, 1114-1122.	1.7	42
1001	Unsustained complete response of less than 24â€‰months after autologous stem cell transplantation predicts aggressive myeloma with short survival. Hematological Oncology, 2014, 32, 205-211.	0.8	3
1002	Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 670-676.	1.7	82
1003	Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: A singleâ€center clinical analysis. Thoracic Cancer, 2015, 6, 359-362.	0.8	18
1004	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica, 2015, 100, 100-106.	1.7	33
1005	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood, 2015, 126, 2284-2290.	0.6	201
1006	Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. Internal Medicine, 2015, 54, 1711-1715.	0.3	4
1008	Highâ€dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma. British Journal of Haematology, 2015, 171, 355-365.	1.2	3

#	Article	IF	Citations
1009	A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Experimental Hematology and Oncology, 2015, 5, 11.	2.0	13
1010	Longâ€term outcomes for newlyâ€diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of <scp>CALGB</scp> (Alliance) 10301, a multicentre phase <scp>II</scp> study. British Journal of Haematology, 2015, 171, 373-377.	1.2	10
1011	Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. British Journal of Haematology, 2015, 171, 52-59.	1.2	32
1012	Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Anti-Cancer Drugs, 2015, 26, 1078-1082.	0.7	8
1013	18F-FDG PET Increases Visibility of Bone Lesions in Relapsed Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, 291-296.	0.7	8
1014	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma. Chinese Medical Journal, 2015, 128, 1215-1222.	0.9	16
1015	The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2015, 8, 775.	1.0	7
1016	Identification of the key genes connected with plasma cells of multiple myeloma using expression profiles. OncoTargets and Therapy, 2015, 8, 1795.	1.0	8
1017	Deep Response in Multiple Myeloma: A Critical Review. BioMed Research International, 2015, 2015, 1-7.	0.9	32
1018	Infrequent DNA methylation ofmiR-9-1andmiR-9-3in multiple myeloma. Journal of Clinical Pathology, 2015, 68, 557-561.	1.0	20
1019	Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica, 2015, 100, 385-391.	1.7	26
1020	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2959-2961.	0.6	2
1021	Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. Expert Opinion on Biological Therapy, 2015, 15, 149-154.	1.4	9
1022	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 2015, 100, 1327-1333.	1.7	68
1023	Diagnosis and staging. , 2015, , 15-28.		0
1024	Bortezomib-Containing Regimens Are Effective in Multiple Myeloma - Results of a Non-Interventional Phase IV Study. Oncology Research and Treatment, 2015, 38, 167-173.	0.8	6
1025	The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 2015, 39, 380-387.	0.4	17
1026	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomibâ€melphalanâ€prednisone in the phase III VISTA study. American Journal of Hematology, 2015, 90, 314-319.	2.0	58

#	Article	IF	Citations
1027	Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplantation, 2015, 50, 204-208.	1.3	43
1028	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. American Journal of Hematology, 2015, 90, E86-91.	2.0	7
1029	Urine â€“ A waste or the future of regenerative medicine?. Medical Hypotheses, 2015, 84, 344-349.	0.8	14
1030	Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Science, 2015, 106, 179-185.	1.7	18
1031	The effect of the dual PI3K and <scp>mTOR</scp> inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 2015, 94, 343-354.	1.1	29
1032	Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy, 2015, 119, 186-194.	1.4	6
1033	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature Reviews Clinical Oncology, 2015, 12, 286-295.	12.5	97
1034	Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Annals of Hematology, 2015, 94, 1017-1024.	0.8	9
1035	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplantation, 2015, 50, 505-510.	1.3	16
1036	Treatment-related symptom management in patients with multiple myeloma: a review. Supportive Care in Cancer, 2015, 23, 1431-1445.	1.0	34
1037	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2015, 50, 511-516.	1.3	6
1038	Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review. Oncologist, 2015, 20, 210-223.	1.9	91
1039	Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 2015, 29, 387-403.	2.8	48
1040	Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. Critical Reviews in Oncology/Hematology, 2015, 94, 164-178.	2.0	11
1041	High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for â€œDeÂNovoâ€•Multiple Myeloma Patients: A Phase II Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1932-1938.	2.0	20
1043	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood, 2015, 126, 858-862.	0.6	50
1044	Allogeneic transplantation in multiple myeloma â€“ How, when or at all?. Acta Haematologica Polonica, 2015, 46, 224-232.	0.1	0
1045	Performance evaluation of a proliferation chamber with external stirred conditioning tank for expansion of a suspendable stem cell model. Process Biochemistry, 2015, 50, 1110-1118.	1.8	6

#	Article	IF	Citations
1046	Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle et de ThÃ©rapie Cellulaire (SFGM-TC). Biology of Blood and Marrow Transplantation, 2015, 21, 1452-1459.	2.0	8
1047	Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy. Cell Biochemistry and Biophysics, 2015, 71, 457-464.	0.9	16
1048	Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. International Journal of Hematology, 2015, 101, 569-577.	0.7	9
1049	<scp>LDH</scp> is an adverse prognostic factor independent of <scp>ISS</scp> in transplantâ€eligible myeloma patients receiving bortezomibâ€based induction regimens. European Journal of Haematology, 2015, 94, 330-335.	1.1	25
1050	New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood, 2015, 125, 3059-3068.	0.6	256
1051	Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 1712-1721.	3.2	14
1052	Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 2015, 29, 1721-1729.	3.3	123
1053	Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 1330-1334.	2.0	10
1054	Ex Vivoâ€“expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Journal of Immunotherapy, 2015, 38, 24-36.	1.2	154
1055	Comparison of upfront tandem autologousâ€“allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation, 2015, 50, 802-807.	1.3	13
1056	Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology, 2015, 101, 286-294.	0.7	28
1057	Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplantation, 2015, 50, 808-812.	1.3	34
1058	Development of human B cells and antibodies following human hematopoietic stem cell transplantation to Rag2â^'/â^'Î³câ^'/â^' mice. Transplant Immunology, 2015, 32, 144-150.	0.6	2
1059	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 1334-1339.	1.7	44
1060	Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. Oncology, 2015, 89, 196-204.	0.9	5
1061	Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia and Lymphoma, 2015, 56, 608-614.	0.6	14
1062	Phase Ib/II trial of <scp>CYKLONE</scp> (cyclophosphamide, carfilzomib, thalidomide and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 Td	1.2	42
1063	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. International Journal of Hematology, 2015, 102, 670-677.	0.7	5

#	Article	IF	Citations
1064	Paraprotein-related renal disease and amyloid. Medicine, 2015, 43, 533-537.	0.2	1
1065	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	0.8	138
1066	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplantation, 2015, 50, 209-215.	1.3	108
1067	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	13.9	1,144
1068	Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 732-739.	0.8	88
1069	Relationship between tumour necrosis factorâ€related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients. Hematological Oncology, 2015, 33, 199-205.	0.8	2
1070	A phase 2, randomized, doubleâ€blind, placeboâ€controlled study of siltuximab (antiâ€IL6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2015, 90, 42-49.	2.0	116
1071	Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplantation, 2015, 50, 95-99.	1.3	42
1072	The development of potential antibody-based therapies for myeloma. Blood Reviews, 2015, 29, 81-91.	2.8	33
1073	Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. BioMed Research International, 2016, 2016, 1-17.	0.9	17
1074	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget, 2016, 7, 9666-9679.	0.8	33
1075	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. Clinical Cancer Research, 2016, 22, 4559-4566.	3.2	56
1076	Single versus tandem highâ€dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: longâ€term results from the phase <scp>III GMMG</scp>â€<scp>HD</scp>2 trial. British Journal of Haematology, 2016, 173, 731-741.	1.2	50
1077	Cyclophosphamide plus granulocyteâ€colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Journal of Clinical Apheresis, 2016, 31, 423-428.	0.7	15
1078	Doseâ€intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematological Oncology, 2016, 34, 200-207.	0.8	5
1079	<scp>TAK</scp>â€228 (formerly <scp>MLN</scp>0128), an investigational oral dual <scp>TORC</scp>1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, nonâ€Hodgkin lymphoma, or WaldenstrÃ¶m's macroglobulinemia. American Journal of Hematology, 2016, 91, 400-405.	2.0	89
1080	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	0.6	49
1081	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematology,the, 2016, 3, e572-e580.	2.2	39

#	Article	IF	Citations
1082	Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. Journal of International Medical Research, 2016, 44, 1462-1473.	0.4	5
1083	Innovations in treatment and response evaluation in multiple myeloma. Haematologica, 2016, 101, 518-520.	1.7	2
1084	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia, 2016, 30, 2047-2054.	3.3	59
1085	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood, 2016, 127, 3360-3368.	0.6	89
1086	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 2016, 127, 2693-2700.	0.6	66
1087	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 2016, 127, 713-721.	0.6	121
1088	Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 558-562.	0.2	4
1089	Multiple Myeloma Minimal Residual Disease. Cancer Treatment and Research, 2016, 169, 103-122.	0.2	19
1090	Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry Part B - Clinical Cytometry, 2016, 90, 14-20.	0.7	35
1091	A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. British Journal of Haematology, 2016, 172, 745-756.	1.2	18
1092	Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer Journal, 2016, 6, e466-e466.	2.8	17
1093	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncology, The, 2016, 17, 1569-1578.	5.1	164
1094	Revised International Staging System Applied to Real World Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 511-518.	0.2	37
1095	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica, 2016, 101, 1398-1406.	1.7	28
1096	Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). International Journal of Oncology, 2016, 49, 33-50.	1.4	29
1097	Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2016, 104, 596-604.	0.7	9
1098	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Annals of Hematology, 2016, 95, 2033-2041.	0.8	27
1099	Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chinese Journal of Cancer, 2016, 35, 86.	4.9	19

#	Article	IF	Citations
1100	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 2016, 101, 346-355.	1.7	44
1101	Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy. European Journal of Haematology, 2016, 96, 417-424.	1.1	2
1102	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer, 2016, 16, 290.	1.1	5
1103	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 387-394.	0.2	11
1104	A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2016, 103, 25-33.	0.7	14
1105	Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplantation, 2016, 51, 933-937.	1.3	18
1106	Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. Leukemia and Lymphoma, 2016, 57, 2077-2083.	0.6	5
1107	Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro. OncoImmunology, 2016, 5, e1139662.	2.1	30
1108	Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer Journal, 2016, 6, e396-e396.	2.8	27
1109	Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. Leukemia and Lymphoma, 2016, 57, 1716-1718.	0.6	2
1110	Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. British Journal of Cancer, 2016, 114, 7-13.	2.9	30
1111	CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?. Leukemia and Lymphoma, 2016, 57, 335-340.	0.6	7
1112	Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20Âyears. Annals of Hematology, 2016, 95, 63-72.	0.8	11
1113	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia, 2016, 30, 526-535.	3.3	76
1114	Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant. Leukemia and Lymphoma, 2016, 57, 973-976.	0.6	6
1115	A randomized study of melphalan 200â€‰mg/m2 vs 280â€‰mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplantation, 2016, 51, 67-71.	1.3	27
1116	Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology, 2016, 278, 449-457.	3.6	7
1117	Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrology Dialysis Transplantation, 2016, 31, 64-72.	0.4	46

#	Article	IF	Citations
1118	Proteasome inhibitors and <scp>IM</scp>iDs can overcome some highâ€risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology, 2016, 96, 46-54.	1.1	35
1119	Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia, 2017, 31, 1922-1927.	3.3	63
1120	An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. AAPS Journal, 2017, 19, 557-567.	2.2	9
1121	Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Investigation, 2017, 35, 195-201.	0.6	11
1122	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and metaâ€regression analysis. European Journal of Haematology, 2017, 98, 563-568.	1.1	10
1123	Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Cancer Science, 2017, 108, 461-468.	1.7	16
1124	Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research, 2017, 23, 4550-4555.	3.2	23
1125	Carfilzomibâ€“lenalidomideâ€“dexamethasone vs lenalidomideâ€“dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer Journal, 2017, 7, e554-e554.	2.8	54
1126	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer Chemotherapy and Pharmacology, 2017, 79, 1141-1149.	1.1	25
1127	Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leukemia Research, 2017, 59, 75-84.	0.4	30
1128	Processing of biphasic calcium phosphate ceramics for culturing of bone marrow stem cells. Journal of Materials Research, 2017, 32, 3260-3270.	1.2	3
1129	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Biology of Blood and Marrow Transplantation, 2017, 23, 1193-1202.	2.0	14
1130	Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia, 2017, 31, 1463-1466.	3.3	20
1131	Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trial. British Journal of Haematology, 2017, 179, 586-597.	1.2	30
1132	Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 2017, 7, e617-e617.	2.8	45
1133	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	2.2	132
1134	Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology, 2017, 93, 295-301.	0.9	4
1135	Standardisation of minimal residual disease in multiple myeloma. European Journal of Cancer Care, 2017, 26, e12732.	0.7	9

#	Article	IF	Citations
1136	A Phase 1 and 2 study of Filanesib alone and in combination with lowâ€dose dexamethasone in relapsed/refractory multiple myeloma. Cancer, 2017, 123, 4617-4630.	2.0	43
1137	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clinics in Laboratory Medicine, 2017, 37, 821-853.	0.7	20
1138	Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. International Journal of Hematology, 2017, 106, 541-551.	0.7	13
1139	Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. International Journal of Hematology, 2017, 105, 326-334.	0.7	6
1140	A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomideâ€containing regimens. British Journal of Haematology, 2017, 176, 440-447.	1.2	11
1141	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia, 2017, 31, 107-114.	3.3	98
1142	Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 50-62.	3.3	37
1143	Association between complete response and outcomes in transplantâ€eligible myeloma patients in the era of novel agents. European Journal of Haematology, 2017, 98, 269-279.	1.1	28
1144	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2017, 52, 567-569.	1.3	5
1145	The Evolution of Prognostic Factors in Multiple Myeloma. Advances in Hematology, 2017, 2017, 1-11.	0.6	49
1146	Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. Cancer Management and Research, 2017, Volume 9, 287-298.	0.9	16
1147	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	0.8	248
1148	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica, 2023, 108, 890-897.	1.7	65
1149	Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Clinical Therapeutics, 2018, 40, 480-494.e23.	1.1	27
1150	Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions. Seminars in Hematology, 2018, 55, 13-18.	1.8	19
1151	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 400-407.e1.	0.2	7
1153	Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological Oncology, 2018, 36, 436-444.	0.8	13
1154	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	0.8	14

#	Article	IF	Citations
1155	Analysis of longâ€term survival in multiple myeloma after firstâ€line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Medicine, 2018, 7, 307-316.	1.3	42
1156	Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. Leukemia Research, 2018, 68, 90-97.	0.4	6
1157	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology, 2018, 200, 2581-2591.	0.4	19
1158	Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. Journal of Oncology Pharmacy Practice, 2018, 24, 281-289.	0.5	5
1159	A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1008-1014.	0.6	8
1160	Modelâ€Based Metaâ€Analysis for Multiple Myeloma: A Quantitative Drugâ€Independent Framework for Efficient Decisions in Oncology Drug Development. Clinical and Translational Science, 2018, 11, 218-225.	1.5	9
1161	Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e77-e84.	0.2	9
1162	Epigenetic silencing of EVL/miR-342 in multiple myeloma. Translational Research, 2018, 192, 46-53.	2.2	14
1163	EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist, 2018, 23, 631-636.	1.9	30
1164	Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e69-e75.	0.2	6
1165	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 2018, 32, 252-262.	3.3	234
1166	Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leukemia and Lymphoma, 2018, 59, 1920-1926.	0.6	13
1167	Epigenetic silencing of LPP/miR-28 in multiple myeloma. Journal of Clinical Pathology, 2018, 71, 253-258.	1.0	15
1168	Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials. Oncotarget, 2018, 9, 23704-23717.	0.8	17
1169	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer Journal, 2018, 8, 109.	2.8	170
1170	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2018, 379, 1811-1822.	13.9	413
1171	Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 327-338.	0.7	4
1172	Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and <scp>PK</scp>/<scp>PD</scp> trial. Cancer Science, 2018, 109, 3245-3252.	1.7	6

#	Article	IF	Citations
1173	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4â€year followâ€up and analysis of relative progressionâ€free survival from the randomized ELOQUENTâ€2 trial. Cancer, 2018, 124, 4032-4043.	2.0	118
1174	Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Annals of Hematology, 2018, 97, 2455-2463.	0.8	16
1175	Pathway-structured predictive modeling for multi-level drug response in multiple myeloma. Bioinformatics, 2018, 34, 3609-3615.	1.8	3
1176	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Annals of Hematology, 2018, 97, 1671-1682.	0.8	17
1177	High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. Annals of Hematology, 2018, 97, 1879-1887.	0.8	2
1178	Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1325-1327.	0.9	0
1179	Bortezomibâ€based therapy for relapsed/refractory multiple myeloma in realâ€world medical practice. European Journal of Haematology, 2018, 101, 556-565.	1.1	15
1180	Activation of ER Stress-Dependent miR-216b Has a Critical Role in Salvia miltiorrhiza Ethanol-Extract-Induced Apoptosis in U266 and U937 Cells. International Journal of Molecular Sciences, 2018, 19, 1240.	1.8	25
1181	Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1399-1405.	2.0	24
1182	Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression. BMC Cancer, 2018, 18, 551.	1.1	11
1183	Doseâ€intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematological Oncology, 2018, 36, 671-678.	0.8	10
1184	High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan. Bone Marrow Transplantation, 2018, 53, 1349-1350.	1.3	0
1185	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. JAMA Oncology, 2018, 4, e183267.	3.4	63
1186	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 533-540.	0.2	9
1187	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood, 2018, 132, 670-672.	0.6	42
1188	Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Science, 2019, 110, 2924-2932.	1.7	7
1189	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2134-2142.	2.0	52
1190	Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology, 2019, 110, 447-457.	0.7	1

#	Article	IF	Citations
1191	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	2.2	42
1192	Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematological Oncology, 2019, 37, 586-594.	0.8	8
1193	Bortezomib retreatment for relapsed and refractory multiple myeloma in realâ€world clinical practice. Health Science Reports, 2019, 2, e104.	0.6	16
1194	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia, 2019, 33, 1736-1746.	3.3	45
1195	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leukemia Research, 2019, 83, 106172.	0.4	15
1196	Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014â€04 (Etoile du Nord) trial. British Journal of Haematology, 2019, 187, 319-327.	1.2	18
1197	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. European Journal of Haematology, 2019, 103, 255-267.	1.1	6
1198	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 570-578.e1.	0.2	20
1199	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 2019, 19, 504.	1.1	25
1200	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	1.8	23
1201	Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study. Palliative Medicine, 2019, 33, 541-551.	1.3	30
1202	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood, 2019, 133, 2664-2668.	0.6	11
1203	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	2.8	11
1204	Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey. Transfusion and Apheresis Science, 2019, 58, 313-317.	0.5	0
1205	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 41.	2.8	80
1206	Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. Oncology Reviews, 2019, 13, 377.	0.8	4
1207	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	0.7	4
1208	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 17.	2.8	35

#	Article	IF	Citations
1209	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.2	9
1210	Efficacy and safety of autologous stem cell transplantation in patients aged â‰¥â€‰65 years with multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2019, 54, 1595-1604.	1.3	12
1211	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CDâ€“56-positive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 29-34.	0.2	53
1212	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia, 2019, 33, 313-318.	3.3	17
1213	Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. International Journal of Hematology, 2019, 109, 98-106.	0.7	10
1214	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 2020, 55, 419-430.	1.3	6
1215	Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. Leukemia and Lymphoma, 2020, 61, 27-36.	0.6	4
1216	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma, 2020, 61, 680-690.	0.6	9
1217	Conditioningâ€based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991â€2012) on behalf of EBMT CMWP. European Journal of Haematology, 2020, 104, 181-189.	1.1	7
1218	Therapeutic Advances in the Management of Smoldering Myeloma. American Journal of Therapeutics, 2020, 27, e194-e203.	0.5	0
1219	Cytokine profile in multiple myeloma. Cytokine, 2020, 136, 155271.	1.4	29
1220	Allogeneic Transplantation in Multiple Myelomaâ€”Does It Still Have a Place?. Journal of Clinical Medicine, 2020, 9, 2180.	1.0	17
1221	CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Antiâ€“PD-L1 Treatment. Cancer Immunology Research, 2020, 8, 1163-1179.	1.6	17
1222	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	2.2	34
1223	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 797-803.	0.2	5
1224	Minimal residual disease in multiple myeloma: are we there yet?. International Journal of Hematologic Oncology, 2020, 9, IJH29.	0.7	0
1225	Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 1280-1287.	2.0	7
1226	Comparison of efficacy from two different dosing regimens of bortezomib: an exposureâ€“response analysis. British Journal of Haematology, 2020, 189, 860-868.	1.2	3

#	Article	IF	Citations
1227	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1414-1424.	2.0	5
1228	Randomized, placeboâ€controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. EJHaem, 2020, 1, 94-102.	0.4	8
1229	MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1â€“2a trial. Lancet Haematology,the, 2020, 7, e381-e394.	2.2	59
1230	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	0.8	17
1231	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Annals of Hematology, 2020, 99, 1709-1725.	0.8	12
1232	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 480-489.	0.2	7
1233	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia, 2021, 35, 1134-1144.	3.3	36
1234	Multiple Myelomaâ€”Effect of Induction Therapy on Transplant Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 80-90.e5.	0.2	10
1235	Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood. International Journal of Laboratory Hematology, 2021, 43, 403-408.	0.7	13
1236	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer, 2021, 21, 73.	1.1	20
1237	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical Hematology International, 2021, 3, 27.	0.7	1
1238	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	1.2	19
1239	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Advances, 2021, 5, 1340-1343.	2.5	7
1240	Comparison of [18F]FDG PET/CT and MRI for Treatment Response Assessment in Multiple Myeloma: A Meta-Analysis. Diagnostics, 2021, 11, 706.	1.3	8
1241	Use of endpoints in multiple myeloma randomized controlled trials over the last 15â€‰years: A systematic review. American Journal of Hematology, 2021, 96, 690-697.	2.0	13
1243	Feature-weighted ordinal classification for predicting drug response in multiple myeloma. Bioinformatics, 2021, 37, 3270-3276.	1.8	4
1244	Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 345-354.e4.	0.2	4
1245	Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1). Japanese Journal of Clinical Oncology, 2021, 51, 1059-1066.	0.6	0

#	Article	IF	Citations
1246	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology, 2021, 96, 925-933.	2.0	7
1247	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. Blood, 2021, 138, 1901-1905.	0.6	23
1248	Full or intensityâ€reduced highâ€dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. European Journal of Haematology, 2021, 107, 529-542.	1.1	3
1249	Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 44-51.	0.2	5
1250	Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma. Egyptian Academic Journal of Biological Sciences C Physiology and Molecular Biology, 2021, 13, 37-46.	0.0	0
1251	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 2021, 13, 4706.	1.7	11
1252	A phase I/ II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second doseâ€expansion cohort. American Journal of Hematology, 2021, 96, 428-435.	2.0	6
1253	Myeloma. , 0, , 681-702.		2
1255	Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia, 2018, 32, 383-390.	3.3	152
1256	Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. The Hematology Journal, 2004, 5, 216-221.	2.0	10
1257	Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. The Hematology Journal, 2004, 5, 222-226.	2.0	32
1258	The Potential Role of Proteasome Inhibitors in the Treatment of Lung Cancer. Clinical Cancer Research, 2004, 10, 4263s-4265s.	3.2	21
1259	T cell progenitor therapyâ€"facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight, 2017, 2, .	2.3	18
1260	Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.. Blood, 2006, 108, 3552-3552.	0.6	10
1261	Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.. Blood, 2007, 110, 3605-3605.	0.6	3
1262	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood, 2000, 96, 355-357.	0.6	1
1263	Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013, 8, e64354.	1.1	40
1264	The Glycome of Normal and Malignant Plasma Cells. PLoS ONE, 2013, 8, e83719.	1.1	12

#	Article	IF	Citations
1265	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE, 2014, 9, e101819.	1.1	49
1266	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS ONE, 2015, 10, e0138248.	1.1	7
1267	A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS ONE, 2017, 12, e0171205.	1.1	39
1268	Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget, 2017, 8, 39805-39817.	0.8	13
1269	Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma. Oncotarget, 2017, 8, 25637-25649.	0.8	10
1270	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget, 2015, 6, 1874-1883.	0.8	42
1271	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
1272	Bortezomib (Velcade?) in the treatment of multiple myeloma. Therapeutics and Clinical Risk Management, 2006, 2, 271-279.	0.9	197
1273	Estudio bibliomÃ©trico: 45 aÃ±os de literatura biomÃ©dica en trasplante de cÃ©lulas madre hematopoyÃ©ticas. Medunab, 2018, 20, 319-326.	0.0	1
1275	Long-Term Reversibility of Renal Dysfunction Associated to Light Chain Deposition Disease with Bortezomib and Dexamethasone and High Dose Therapy and Autologous Stem Cell Transplantation. Clinics and Practice, 2011, 1, 205-208.	0.6	7
1276	High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian Journal of Medical Research, 2019, 149, 730.	0.4	23
1277	Predicting Minimal Residual Disease in Multiple Myeloma: Allelic-Specific Oligonucleotide Real-Time Quantitative PCR or Multi Parametric Flow Cytometry. Journal of Genetic Syndromes & Gene Therapy, 2012, 03, .	0.2	2
1278	Once-weekly Bortezomib in Combination with Reduced-dose Dexamethasone and Continuous Low-dose Oral Cyclophosphamide for Elderly Patients with Multiple Myeloma. Journal of Hematology & Thromboembolic Diseases, 2017, 05, .	0.1	1
1279	The levels of sMUC-1 in patients with multiple myeloma. Folia Histochemica Et Cytobiologica, 2012, 49, 654-658.	0.6	2
1280	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
1281	Significance of Oligoclonal Bands after Stem Cell Transplantation in Multiple Myeloma Cases. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1483-1486.	0.5	8
1282	Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Science, 2021, 112, 5034-5045.	1.7	15
1283	The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research, 2021, 11, 100.	1.1	12

#	Article	IF	Citations
1284	An Allogeneic Multiple Myeloma GM-CSFâ€“Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical Cancer Research, 2021, 27, 6696-6708.	3.2	8
1285	Realâ€world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45â€year period. British Journal of Haematology, 2022, 196, 649-659.	1.2	6
1286	Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood, 2000, 96, 2697-2702.	0.6	0
1287	Multiples Myelom. , 2004, , 1793-1813.		0
1288	Allogeneic Transplantation in Multiple Myeloma. , 2004, , 183-203.		0
1289	Fluid Retention During Thalidomide Therapy for Refractory Multiple Myelomas. Journal of Clinical and Experimental Hematopathology: JCEH, 2004, 44, 63-66.	0.3	0
1290	Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma. , 2004, , 301-305.		0
1291	Innovative approaches for diagnosis and monitoring. , 2004, , 164-178.		0
1292	Principles of management. , 2004, , 203-219.		0
1293	Delayed Resolution of Nephrotic Syndrome Following Stem Cell Transplant for Amyloidosis (Al). , 2004, , 130-132.		0
1296	Multiples Myelom. Pharma-Kritik (discontinued), 2005, 26, .	0.0	0
1297	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	0.6	1
1298	Multiples Myelom. , 2006, , 3165-3205.		0
1299	Multiples Myelom und verwandte Plasmazellerkrankungen. , 2007, , 1-12.		0
1300	Plasmazellerkrankungen. , 2007, , 493-510.		0
1302	Role of Autologous Stem Cell Transplantation in Multiple Myeloma. , 2008, , 79-90.		0
1304	Evolving Indications for Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Other Plasma Cell Disorders. Cancer Treatment and Research, 2009, 144, 317-355.	0.2	0
1305	Thalidomide Therapy for Refractory Multiple Myeloma. Yamaguchi Medical Journal, 2009, 58, 97-103.	0.1	0

#	Article	IF	Citations
1306	Analysis of Adverse Events of Bortezomib Therapy in Patients with Multiple Myeloma. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2009, 35, 387-394.	0.0	1
1307	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 2727-2727.	0.6	0
1308	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood, 2009, 114, 1187-1187.	0.6	0
1309	Unrelated Stem Cell Transplantation After Reduced Intensity Conditioning for Patients with Multiple Myeloma Relapsing After Autologous Transplantation A Prospective Multicenter Phase II Study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2009, 114, 2308-2308.	0.6	0
1311	Bortezomib in Systemic Light-Chain Amyloidosis. , 2011, , 135-148.		0
1312	Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss Medical Weekly, 2010, 140, w13054.	0.8	4
1314	HÃmatologische und onkologische Erkrankungen. , 2011, , 607-718.		0
1315	Efficacy of Long-Term Treatment with Low-Dose Thalidomide for Patients with Relapsed/Refractory Multiple Myeloma. International Journal of Clinical Medicine, 2011, 02, 570-575.	0.1	0
1317	Chapter 8 The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients. , 0, , .		2
1318	Targeting the BAFF/APRIL Cytokine Network in Multiple Myeloma. , 2013, , 187-202.		0
1319	Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders. World Journal of Hematology, 2013, 2, 6.	0.1	0
1320	Long-term remission in patients with plasma cell myeloma after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation:. Journal of Hematopoietic Cell Transplantation, 2013, 2, 25-31.	0.1	0
1321	FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS. Acta Medica (Hradec Kralove), 2013, 56, 9-13.	0.2	2
1322	Up-Regulating Telomerase and Tumor Suppression: A Two-Step Strategy to Boost Hematopoietic Stem Cell Transplantation. Journal of Stem Cell Research & Therapy, 2013, s3, .	0.3	1
1323	Criteria for Diagnosis and Response. , 2014, , 1-15.		0
1324	Acknowledgments / The Authors. , 2013, , 295-295.		0
1325	Bortezomib-Based Salvage Chemotherapy in Refractory/Relapsed Multiple Myeloma Patients: A Single Center Experience in Real Clinical Practice. Korean Journal of Medicine, 2015, 88, 537.	0.1	0
1326	The Role of Serum Free Light Chain and M-Protein Measurements in Determining Recurrent Disease in Multiple Myeloma After Stem Cell Transplantation. International Clinical Pathology Journal, 2016, 2, .	0.1	0

#	Article	IF	Citations
1327	Overview of cost-effectiveness analysis and health state utilities in multiple myeloma and estimations of health state utilities from real-world macedonian data. Makedonsko Farmacevtski Bilten, 2016, 62, 25-36.	0.0	0
1328	Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma. Clinical Hematology International, 2019, 1, 205-219.	0.7	1
1329	Quantitative MRI biomarker for treatment response assessment of multiple myeloma: robustness evaluation using independent test set of prospective cases. , 2019, , .		0
1330	RELATIONSHIP BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS IN CYTOKINE GENES AND CLINICAL LABORATORY PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA. Medical Immunology (Russia), 2019, 21, 703-714.	0.1	1
1331	Bone marrow plasma cell ratio, is it must to evaluate before autologous stem cell transplantation in multiple myeloma?. Medical Science and Discovery, 2020, 7, 470-474.	0.1	0
1332	Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2022, 218, 602-613.	1.0	14
1333	REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021012.	0.5	5
1334	HÃmatologische und onkologische Erkrankungen. , 2020, , 329-335.		0
1337	Multiples Myelom. , 0, , 421-455.		0
1338	Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clinical Biochemist Reviews, 2009, 30, 113-8.	3.3	33
1339	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, 1, 265-77.	4.7	1
1340	A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma. International Journal of Clinical and Experimental Medicine, 2015, 8, 6743-54.	1.3	9
1344	Early and late relapses of multiple myeloma after autologous haematopoietic stem cell transplantation. Gematologiya I Transfuziologiya, 2021, 66, 512-525.	0.1	0
1345	Multiples Myelom. , 2016, , 1-17.		0
1346	Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. Frontiers in Oncology, 2021, 11, 800309.	1.3	1
1347	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomarker Research, 2022, 10, 1.	2.8	22
1348	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. British Journal of Haematology, 2022, 197, 82-96.	1.2	9
1349	Plasma cell quantification in bone marrow by computer-assisted image analysis. Histology and Histopathology, 2006, 21, 951-6.	0.5	15

#	Article	IF	Citations
1350	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 1096-1104.		0
1352	Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Acta Clinica Belgica, 2011, 66, 371-5.	0.5	5
1355	Multiple Myeloma: Impact of Time to Transplant on the Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e826-e835.	0.2	4
1356	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplantation and Cellular Therapy, 2022, 28, 367.e1-367.e9.	0.6	4
1357	MRD in multiple myeloma: does CR really matter?. Blood, 2022, 140, 2423-2428.	0.6	12
1358	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2022, 9, e403-e414.	2.2	23
1360	Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome. BMC Cancer, 2022, 22, .	1.1	1
1361	Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis. Clinical Cancer Research, 2005, 11, 1210-1218.	3.2	46
1362	Myeloma and Leukemia. , 2023, , 503-528.		0
1364	Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers, 2022, 14, 5165.	1.7	4
1365	Risk and response adapted therapy following autologous stem cell transplant in patients with newly		